

FORM PTO-1390 (REV 1-98)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER 82351.0008	
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371				U.S. APPLICATION NUMBER (known, see 37 C.F.R. 1.5) 09/647270	
INTERNATIONAL APPLICATION NO. PCT/US99/06700 ✓		INTERNATIONAL FILING DATE 26 March 1999 (26.03.99) ✓		PRIORITY DATE CLAIMED 27 March 1998 (27.03.98)	
TITLE OF INVENTION		NOVEL HIV INTEGRASE INHIBITORS AND HIV THERAPY BASED ON DRUG COMBINATIONS INCLUDING INTEGRASE INHIBITORS ✓			
APPLICANT(S) FOR DO/EO/US		ROBINSON, W., Edward, Jr.; KING, Peter J.; REINECKE, Manfred G. ✓			
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:					
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(1). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 					
Items 11. to 16. below concern document(s) or information included:					
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. 12. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 C.F.R. 3.28 and 3.31 is included. 13. <input type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information: <ol style="list-style-type: none"> 1. Copy of PCT/IB/332 2. Copy of PCT/IB/306 3. Copy of PCT/IB/301 4. Copy of Response to Written Opinion 5. Copy of PCT Published Application 6. Verified Statement Claiming Small Entity Status 					

Transmittal Letter to the United States Designated Office (DO/US)—Entry Into National Stage under 35 U.S.C. 371—PTO 1390 [13-7]

U.S. APPLICATION NO. (if known, see 37 C.F.R. 1.53) <div style="font-size: 24pt; font-weight: bold; margin-top: 5px;">09/647270</div>	INTERNATIONAL APPLICATION NUMBER PCT/US99/06700	ATTORNEY'S DOCKET NUMBER 82351.0008
---	---	---

17. ☒ The following fees are submitted:

BASIC NATIONAL FEE (37 C.F.R. 1.492(a)(1)-(5)):

Neither international preliminary examination fee (37 C.F.R. 1.482) nor international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO of JPO\$[970/485]

International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO\$[840/420]

International preliminary examination fee (37 C.F.R. 1.482) not paid to USPTO but international search fee (37 C.F.R. 1.445(a)(2)) paid to USPTO\$[760/380]

International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)\$[670/335]

International preliminary examination fee (37 C.F.R. 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4)..... \$96

ENTER APPROPRIATE BASIC FEE AMOUNT =

Surcharge of \$130.00 for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 C.F.R. 1.492(e)).

CLAIMS	NUMBER FILED	NUMBER ALLOWED	NUMBER EXTRA	RATE		
Total claims	23	20	3 LG=\$18/SM=\$ 9	\$18.00	54.00	
Independent claims	6	3	3 LG=\$78/SM=\$39	\$78.00	234.00	
MULTIPLE DEPENDENT CLAIM(S) (if applicable)				LG=\$260/SM=\$130 + \$260.00	\$ 0	
TOTAL OF ABOVE CALCULATIONS =					\$ 1,088.00	
Reduction of 1/2 for filing by small entity, if applicable. Verified Small Entity Statement must also be filed (Note 37 C.F.R. 1.9, 1.27, 1.28).					544.00	
SUBTOTAL =					544.00	
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 C.F.R. 1.492(f)).					\$ 0	
TOTAL NATIONAL FEE =					544.00	
Fee for recording the enclosed assignment (37 C.F.R. 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 C.F.R. 3.28, 3.31). \$40.00 per property					\$ 0	
TOTAL FEES ENCLOSED =					544.00	
\$					Amt. Refunded	\$
					Amt. charged	

CALCULATIONS PTO USE ONLY

a. ☒ Checks in the amounts of \$544.00 and \$ 0 to cover the above fees are enclosed.

b. ☐ Please charge my Deposit Account No. 50-1314 in the amount of \$ 0 to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-1314. A duplicate copy of this sheet is enclosed.

NOTE: Where an appropriate time limit under 37 C.F.R. 1.494 or 1.495 has not been met, a petition to revive (37 C.F.R. 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

HOGAN & HARTSON L.L.P.
 500 South Grand Avenue, Suite 1900
 Los Angeles, California 90071
 Phone: 213-337-6700
 Fax: 213-337-6701

Stefan J. Kirchanski

SIGNATURE
 Stefan J. Kirchanski
 REG.NO. 36,568

EL 589 805 703 US
 September 27, 2000

09-27-2000 12:51pm From-

T-248 P.002/005 F-508

Docket No. 82351.0008

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant or Patentee: ROBINSON, W., Edward, Jr.

Group No.: Not assigned

KING, Peter J.

Serial or Patent No.:

REINECKE, Manfred G.

Not assigned

Examiner: Not assigned

Filed or issued:

Filed herewith

For:

NOVEL HIV INTEGRASE
INHIBITORS AND HIV THERAPY
BASED ON DRUG COMBINATIONS
INCLUDING INTEGRASE
INHIBITORS

VERIFIED STATEMENT CLAIMING SMALL ENTITY STATUS
(37 C.F.R. 1.9(c-f) and 1.27 (b-d))

1. IDENTIFICATION OF PERSON MAKING STATEMENT AND RIGHTS AS A SMALL ENTITY

I hereby state that I am:

(a) Independent Inventor



a below-named independent inventor, and that I qualify as an independent inventor, as defined in 37 C.F.R. 1.9(c) for purposes of paying reduced fees under Section 41(a) and (b) of Title 35, United States Code, to the Patent and Trademark Office with regard to the invention entitled ____ described in:



the specification filed herewith



Application Serial No. ____ filed ____



Patent No. ____ issued ____

(b) Non-Inventor Supporting a Claim by Another



making this statement to support a claim by ____ for a small entity status for purposes of paying reduced fees under Sections 41(a) and (b) of Title 35, United States Code. I hereby state that I should qualify as an independent inventor as defined in 37 C.F.R. 1.9(c) for purposes of paying reduced fees under Sections 41(a) and (b) of Title 35, United States Code, if I had made the invention entitled ____ described in:



the specification filed herewith



Application Serial No. ____ filed ____



Patent No. ____ issued ____

(c) Small Business Concern



the owner of the small business concern identified below.



an official of the small business concern empowered to act on behalf of the concern identified below.

NAME OF CONCERN

ADDRESS OF CONCERN

I hereby declare that the above-identified small business concern qualifies as a small business concern as defined in 13 C.F.R. 121.3-18, and reproduced in 37 C.F.R. 1.9(d), for purposes of paying reduced fees under Sections 41(a) and (b) of Title 35, United States Code, in that the number of employees of the concern, including those of its affiliates, does not exceed 500 persons. For purposes of this statement, (1) the number of employees of the business concern is the average over the previous fiscal year of the concern of the persons employed on a

09-27-2000 12:51pm From-

T-248 P.003/005 F-508

full-time, part-time or temporary basis during each of the pay periods of the fiscal year, and (2) concerns are affiliates of each other when either, directly or indirectly, one concern controls or has the power to control the other, or a third party or parties controls or has the power to control both.

I hereby declare that rights under contract of law have been conveyed to and remain with the small business concern identified above with regard to the invention entitled ____ by inventor(s) ____ described in:

- ☐ the specification filed herewith
☐ Application Serial No. _____, filed ____
☐ Patent No. _____, issued ____

If the right held by the above-identified small business concern is not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 C.F.R. 1.9(d) or by any concern which would not qualify as a small business concern under 37 C.F.R. 1.9(d) or a nonprofit organization under 37 C.F.R. 1.9(e).

(d) Non-Profit Organization

I hereby declare that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF CONCERN	THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
ADDRESS OF CONCERN	1111 Franklin Street, 12 th Floor Oakland, California 94607-5200 United States of America

TYPE OF ORGANIZATION

- ☒ University or Other Institution of Higher Education
☐ Tax Exempt Under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3))
☐ Nonprofit Scientific or Educational Under Statute of State of the United States of America
 Name of State ____
 Citation of Statute ____
☐ Would Qualify as Tax Exempt Under Internal Revenue Service Code (26 U.S.C. 501(a) and 501(c)(3)), if located in the United States of America
☐ Would Qualify as Nonprofit Scientific or Educational Under Statute of State of the United States of America if Located in the United States of America
 Name of State ____
 Citation of Statute ____

I hereby declare that the nonprofit organization identified above qualifies as a nonprofit organization, as defined in 37 C.F.R. 1.9(e), for purposes of paying reduced fees under Sections 41(a) and (b) of Title 35, United States Code, with regard to the invention entitled NOVEL HIV INTEGRASE INHIBITORS AND HIV THERAPY BASED ON DRUG COMBINATIONS INCLUDING INTEGRASE INHIBITORS by inventor(s) ROBINSON, W. Edward, Jr.; KING, Peter J.; REINECKE, Manfred G. described in:

- ☒ the specification filed herewith
☐ Application Serial No. _____, filed ____
☐ Patent No. _____, issued ____

If the rights held by the nonprofit organization are not exclusive, each individual, concern or organization having rights to the invention is listed below and no rights to the invention are held by any person, other than the inventor, who could not qualify as a small business concern under 37 C.F.R. 1.9(d) or by any concern which would not qualify as a small business concern under 37 C.F.R. 1.9(d) or a nonprofit organization under 37 C.F.R. 1.9(e)

II. OWNERSHIP OF INVENTION BY DECLARANT

I hereby declare that rights under contract or law remain with and/or have been conveyed to the above-identified

09-27-2000 12:51pm From-

T-248 P.004/005 P-508

☐ individual
(item (a) or (b) above)

☐ small business concern
(item (c) above)

☒ nonprofit organization
(item (d) above)

EXCEPT, that if the rights held are not exclusive, each individual, concern or organization having rights to the invention is listed below* and no rights to the invention are held (1) by any individual who could not be classified as an independent inventor under 37 C.F.R. 1.9(c) if that individual had made the invention, (2) any concern which would not qualify as a small business concern under 37 C.F.R. 1.9(d) or (3) a nonprofit organization under 37 C.F.R. 1.9(e).

☒ no such person, concern or organization
the person, concern or organization listed below*

*NOTE: Separate verified statements are required from each named person, concern or organization having rights to the invention availing to their status as small entities. (37 C.F.R. 1.27)

FULL NAME

ADDRESS

☐ INDIVIDUAL

☐ SMALL BUSINESS CONCERN

☐ NONPROFIT ORGANIZATION

FULL NAME

ADDRESS

☐ INDIVIDUAL

☐ SMALL BUSINESS CONCERN

☐ NONPROFIT ORGANIZATION

III. ACKNOWLEDGMENT OF DUTY TO NOTIFY PTO OF STATUS CHANGE

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 C.F.R. 1.28(b)).

IV. DECLARATION

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application, any patent issuing thereon, or any patent to which this verified statement is directed

V. SIGNATURES

(complete only (e) or (f) below)

(e) (NOTE: All inventors must sign the statement)

Date: _____

Signature of Inventor

Date: _____

Signature of Inventor

Date: _____

Signature of Inventor

(f) (NOTE: The title of the person signing on behalf of a concern or nonprofit organization should be specified.)

NAME OF PERSON SIGNING

Linda S. Stevenson

TITLE OF PERSON OTHER THAN OWNER

Manager, Patent Prosecution

ADDRESS OF PERSON SIGNING

Office of Technology Transfer, 5th Floor
1111 Franklin Street, 5th Floor
Oakland, CA 94607-5200

SIGNATURE

Linda S. Stevenson

DATE _____

16/PR+5

Express Mail Label No., EM56101102700

09/647270

Patent Application

36316.5

526 Rec'd 27 SEP 2000

-1-

**NOVEL HIV INTEGRASE INHIBITORS AND HIV THERAPY BASED ON
DRUG COMBINATIONS INCLUDING INTEGRASE INHIBITORS**

5 *Related Applications*

The present application is a Continuation-In-Part of United States Provisional Patent Applications Serial Nos. 60/079,764, filed 27-March-1998, and 60/093,208, filed 17-July-1998; these applications are incorporated herein by reference, and priority is claimed from these applications.

10 This work was supported in part by the Public Health Service, grant AI-41360 from the National Institutes of Allergy and Infectious Diseases, and the Government may have certain rights in this invention.

Background of Invention

1. Field of the Invention

15 The present invention concerns the medical area of treatment of viral infections and more particularly includes novel inhibitors of HIV integrase and combination drug therapies including integrase inhibitors.

2. Description of the Prior Art

20 Infection of an individual with the human immunodeficiency virus (HIV) is understood to be the first step toward the development of acquired immunodeficiency syndrome (AIDS) disease. In nearly all cases where individuals receive no treatment for HIV infection, the proliferation of the virus gives rise to AIDS. As of early 1999, an estimated 33.4 million people are infected with HIV worldwide. Furthermore, the number of people worldwide that became infected with HIV during 1998 is estimated
25 to be 5.8 million. It has also been observed that the annual rate of new infection with

HIV in the entire human population is not declining. Despite this fact, the rate of death due to AIDS has begun to drop in some nations, including the United States, primarily through the recent use of combination drug therapies against HIV infection.

The means by which such therapies counter HIV infection is best understood with reference to the biological mechanisms of the HIV life cycle. HIV is a member of a class of infectious agents known as retroviruses. The infectious form of HIV, a virion, is a particle that consists of a viral genome composed of RNA that is surrounded by proteins encoded by the genome. Infection occurs when an HIV virion enters a susceptible host cell, such as a T lymphocyte within the bloodstream. At this point, one of the viral proteins that comprised the virion, reverse transcriptase (RT), synthesizes a double-stranded DNA copy of the HIV RNA genome. The resulting HIV DNA enters the cell nucleus as part of a stable complex with other virion proteins. This complex contains all the necessary molecular apparatus for integration of the HIV DNA into the host cell's nuclear DNA. Integration, wherein the HIV DNA is covalently inserted into the host cell's genomic DNA, is absolutely required for productive HIV infection. It is only after integration that the HIV DNA can serve as the template for the production of HIV proteins and RNA that will comprise progeny virions. Among these viral proteins is the HIV protease, the activity of which is necessary for proper formation of new virions. This process, from viral entry to new virion production, is termed viral replication. Upon release from an infected host cell, the newly produced virions are capable of infecting more, previously uninfected host cells. It is through successive rounds of HIV replication and productive host cell infection that HIV disease spreads throughout numerous host cells and ultimately progresses to AIDS disease.

Currently, the best clinical results in HIV treatment come from the use of combination drug therapies. These therapies consist of the simultaneous administration of multiple drugs, which potently and selectively target different elements of the HIV life cycle to disrupt or forestall productive HIV infection and progression to AIDS. The potency of a drug refers to its capacity to act efficaciously

at as low a dose as possible, preferably at levels well below those that result in significant amounts of cell death or other signs of cellular toxicity. Selectivity describes the propensity of the drug to act upon a specific target such as unique kind of viral protein. Both of these attributes are of practical importance in the design of therapeutic regimens as they determine the dose, and thus the frequency, cost, and degree of side effects that may occur with use. A further benefit that stems from the use of combinations of drugs derives from a phenomenon known as synergism. With regards to drug therapies, synergism refers to greater than additive effects that are observed when drugs are taken together as opposed to separately. In fact, for HIV, combinations of protease inhibitors and RT inhibitors have demonstrated additive to synergistic effects *in vitro*, which were similar to their *in vivo* effects. A practical consequence of such synergism is that in some cases the dosages of the drugs used in combination may be reduced while maintaining a desired level of therapeutic effect, thus reducing cost, dosage frequency, or the occurrence of undesirable side-effects, or all of these.

As an example, one the most potent combinations in current clinical use consists of two different RT inhibitors in conjunction with an HIV protease inhibitor. In this case, the RT inhibitors, selectively target the activity of HIV reverse transcriptase and serve to reduce the rate at which HIV DNA can be produced from HIV RNA, an event that occurs in the early stages of infection within a given host cell. Meanwhile, the protease inhibitor selectively acts on the HIV protease to interfere with the production of viable virions in the latter stages of infection within a given cell. The use of such combination therapies has become more prevalent, and has been facilitated by the increasing variety of antiretroviral drugs that have been approved for use in humans. There are now at least five nucleoside analogue and non-nucleoside analogue HIV RT inhibitors as well as four HIV protease inhibitors approved for use by the US Food and Drug Administration (FDA). Several more HIV protease inhibitors are likely to be approved within the next year or so.

Although the use of combination drug therapies against HIV has proven to be effective in many patients, the current drug regimens are far from ideal. Adherence to these combination regimes is remarkably difficult in terms of patient compliance, and the drug combinations are quite expensive. Their use has been further hampered

5 because many HIV infected individuals have been on single drug therapies in the past and are currently infected with HIV viruses that are resistant to one or more inhibitors, thereby greatly reducing the effectiveness of the combination drug therapy. As with the RT inhibitors, resistance to protease inhibitors can also occur. Beyond these issues, a number of undesirable side effects, including lipodystrophy syndromes, have

10 surfaced as a consequence of long-term use of protease inhibitors at current dosage levels. These issues make therapy with existing antiviral agents complicated at best and impossible at worst.

Access to a larger variety of antiviral agents mitigates these difficulties to some degree, providing new alternative combinations when a given regimen proves

15 ineffective; furthermore, access to a broader spectrum of selectivity in antiviral agents would greatly increase the number of possible therapeutic combinations. Such a broadened spectrum of selectivity could be achieved if HIV proteins other than RT and the viral protease were the targets of therapeutic drugs. The potential for synergism between drugs with three or more targets should be even greater than is

20 currently found with dual target combinations. Such synergism could lead to greater reductions in dosages with a concomitant reduction in cost and potentially the degree of undesirable side effects. Because one of the major limiting factors in anti-HIV combination therapy is the cost of the antiviral agents, such a dosage reduction could substantially increase the number of patients who could affordably be treated with

25 combination therapy regimens. Further, increasing the number of viral targets would decrease the likelihood that viral strains could emerge that are simultaneously resistant to all therapeutic agents.

Although most clinicians and scientists recognize the need for anti-HIV agents targeted at other HIV proteins to add to current combination therapies, no drugs have

been approved that target the process of HIV integration. As already noted, this stage of the infectious life cycle is absolutely required for all successive stages and the productive infection within an individual that gives rise to disease progression. In principle, if this stage could be targeted with 100% efficiency, further infection of new
5 host cells and disease progression in general could be eliminated. One HIV protein, the enzyme known as integrase (IN), has been shown to have the minimal activities necessary for integration. *In vitro*, the enzyme processes HIV DNA for insertion into double stranded DNA that is found within a host cell's nucleus. Further, IN cleaves double stranded DNA and facilitates the insertion of the pre-processed HIV DNA into
10 the cleavage site. Finally, IN covalently links the HIV DNA to both cleaved ends of the host DNA. The remaining step in integration, filling of small gaps in the DNA sequences that flank the inserted HIV DNA, is probably carried out by host cell DNA repair mechanisms.

Candidate therapeutic compounds that selectively target the activities of IN
15 have been widely sought. The major classes of IN inhibitors that have been reported to date include DNA-binding agents, topoisomerase inhibitors, aurintricarboxylic acid and cosalene analogues, caffeic acid phenylethyl ester (CAPE), curcumin, suramin, anthraquinones, and bis-catechols and other hydroxylated aromatic compounds. There have been two chief problems with nearly all of these compounds, both of which
20 stem, in part, from a widespread reliance on *in vitro* assays of IN activity that utilize purified IN protein. Foremost, selectivity for the IN protein has been difficult to establish. Even zidovudine and other nucleoside analogues, compounds generally used to target HIV RT, have been reported to inhibit HIV IN *in vitro* at sufficiently high concentrations. Aurintricarboxylic acid and related compounds also inhibit RT
25 and other phosphoryltransferase enzymes. Inhibition of IN by DNA-binding agents and topoisomerase inhibitors, such as doxorubicin, is relatively weak and nonselective. In virtually all cases, a protective effect of these small molecule IN inhibitors against HIV infection in live, cultured cells has either been undetectable or not examined.

There are a few exceptional compounds that have been demonstrated to inhibit IN activity potently *in vitro* and HIV replication in live, cultured cells. Octet oligonucleotide inhibitors of HIV IN have been reported that show both kinds of activity and have been entered into phase I clinical trials. Problems attendant with these compounds include high synthetic costs, low bioavailability, and uncertainty about their mechanism of inhibition. In fact, most evidence supports a mechanism of action prior to integration at the level of viral entry. Another class of compounds that holds promise includes the dicaffeoylquinic acids (DCQAs) and the dicaffeoyltartaric acids (DCTAs). These compounds are similar to bis-catechols except that they are more potent, selective inhibitors of HIV IN catalytic activities *in vitro* and are active in blocking replication of HIV in live, cultured cells at non-toxic concentrations. The compounds disclosed below are all structurally similar to the DCQAs and DCTAs and were developed from studies in which the DCTA L-chicoric acid served as a lead compound.

It is clear that new compounds that have potent anti-HIV activity, both *in vitro* and in live cell studies, and that are selective for inhibition of IN would be valuable as anti-HIV therapeutics or lead compounds for anti-HIV therapeutic development. In cases where such pharmacologic inhibitors of IN show demonstrable synergism with existing drugs (or those currently in development) that target other aspects of the HIV life cycle, including the HIV RT inhibitors and HIV protease inhibitors, significant reductions in cost could result in a wider availability of these treatment regimens among a larger number of patients. Even in the absence of synergism with existing anti-HIV agents, the power of the existing drugs makes it unlikely that any new anti-HIV agent will be introduced into patients unless that agent works in combination with existing anti-HIV therapeutics. Also disclosed herein are data demonstrating that the lead DCTA compound L-chicoric acid can act synergistically in combination with established RT inhibitors, protease inhibitors, and simultaneously with both kinds of these established anti-HIV therapeutics. It is expected that the novel compounds presented herein will show behavior similar to L-chicoric acid. Further it is expected

that these compounds will serve as leads for the development of a greater variety of potent, selective inhibitors of HIV IN.

Brief Summary of Invention

5 The present invention includes a group of novel compounds that are demonstrated to potently and selectively inhibit HIV integrase (IN) activity *in vitro* and to potently inhibit HIV replication in live, cultured cells at non-toxic concentrations. These novel, biologically active IN inhibitors are structural analogues of the selective and potent anti-HIV IN compound, L-chicoric acid. Additionally, the
10 use of IN inhibitors of this class in combination with established anti-HIV therapeutics to form synergistic combinations that inhibit HIV replication in live, cultured cells is demonstrated for the first time. The use of this novel class of IN inhibitors in combination with the established classes of anti-HIV compounds, namely reverse transcriptase (RT) inhibitors and protease inhibitors, to interfere with HIV
15 replication provides a synergistic combination therapy.

 In the course of the studies leading up to the present invention, a large number of different analogues of L-chichoric acid were synthesized and investigated in terms of *in vitro* ability to inhibit IN and ability within cell culture to decrease cell death caused by HIV. A number of novel compounds were found that show favorable
20 properties in the assays. Because of their different structural properites some are expected to show superior properties in actual therapeutic regimes. Particularly interesting novel compounds include 2,3-di(3,4-dihydroxydihydroxydihydrocinnamoyl)-L-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-L-tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-L-tartaric acid,
25 2,3-di-(3,4,5-trihydroxybenzoyl)-L-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2,-dicaffeoyl-L-glyceric acid, bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-3,4-dihydrodihydroxybenzylidene succinic acid, 2,3-dicaffeoyl-L-serine, bis-dicaffeoyl-L-isoserine and 1,4-dicaffeoyl-L-lysine.

An especially exciting discovery concerns the combination of the integrase inhibitors with other HIV therapeutics such as reverse transcriptase inhibitors and protease inhibitors. Tests of integrase inhibitors with 2',3'-dideoxycytidine, zidovudine and nelfinavir (protease inhibitor) indicated a potent synergy against reverse transcriptase inhibitor resistant virus. The potential benefit from the addition of integrase inhibitors to combination drug therapies is significant.

Brief Description of the Drawings

Fig. 1a shows a structural diagram of compounds number 1, 2, and 3.

Fig. 1b shows a structural diagram of compound number 19.

Fig. 1c shows a structural diagram of compound number 22.

Fig. 2a shows a structural diagram of compound number 25.

Fig. 2b shows a structural diagram of compound number 26.

Fig. 2c shows a structural diagram of compound number 28.

Fig. 3a shows a structural diagram of compound number 35.

Fig. 3b shows a structural diagram of compound number 36.

Fig. 3c shows a structural diagram of compound number 37.

Fig. 4a shows a structural diagram of compound number 38.

Fig. 4b shows a structural diagram of compound number 39.

Fig. 4c shows a structural diagram of compound number 40.

Fig. 4d shows a structural diagram of compound number 41.

Fig. 5 is a histogram showing the anti-HIV activity of several established anti-HIV therapeutics and L-CCA against 4 different HIV molecular clones.

Fig. 6 is a graph of the anti-HIV activity, as measured by RT release, of various drug combination regimens against HIV_{LAI}. Each point is the mean of triplicate infections; error bars indicate standard deviations.

Fig. 7 is a graph of the anti-HIV activity, as measured by RT release, of various drug combination regimens against HIV_{LAI}. Each point is the mean of triplicate infections; error bars indicate standard deviations.

Fig. 8 is a graph of the anti-HIV activity, as measured by RT release, of various drug combination regimens against the clinically isolated strain HIV_{R45}. Each point is the mean of triplicate infections; error bars indicate standard deviations.

Fig. 9 is a graph of the anti-HIV activity, as measured by RT release, of various drug combination regimens against the clinically isolated strain HIV_{R19}. Each point is the mean of triplicate infections; error bars indicate standard deviations.

Fig 10 is a diagram of Scheme 1 showing the steps in the chemical synthesis of some of the compounds disclosed in the present invention. Abbreviations of compounds are as follows: **OM** = O-methoxycarbonyl = -OCOOMe; **DPM** = diphenylmethyl = -CHPh₂; **CAF** = caffeoyl = -COCH=CH-[3,4-(OH)₂-phenyl]; **BMC**= bismethoxycarbonylcaffeoyl = -COCH=CH-[3,4-(OM)₂-phenyl]. Components of procedures are abbreviated: [A]: ClCOOMe; [B]: Na₂CO₃; [C]: Ph₂CHN₂; [D]: HOAc; [E]: RCOCl; [F]: RCOCl/R₃N; [G]: L-tartaric acid; [H]: [COCl]₂; [I]: SOCl₂.

Fig 11 is a diagram of Scheme 2 showing the steps in the chemical synthesis of some of the compounds disclosed in the present invention. Abbreviations of compounds are as follows: **OM** = O-methoxycarbonyl = -OCOOMe; **DPM** = diphenylmethyl = -CHPh₂; **CAF** = caffeoyl = -COCH=CH-[3,4-(OH)₂-phenyl]; **BMC**= bismethoxycarbonylcaffeoyl = -COCH=CH-[3,4-(OM)₂-phenyl]. Components of procedures are abbreviated: [A]: ClCOOMe; [B]: Na₂CO₃; [C]: Ph₂CHN₂; [D]: HOAc; [E]: RCOCl; [F]: RCOCl/R₃N; [G]: L-tartaric acid; [H]: [COCl]₂; [I]: SOCl₂.

Fig 12 is a diagram of Scheme 3 showing the steps in the chemical synthesis of some of the compounds disclosed in the present invention. Abbreviations of compounds are as follows: **OM** = O-methoxycarbonyl = -OCOOMe; **DPM** = diphenylmethyl = -CHPh₂; **CAF** = caffeoyl = -COCH=CH-[3,4-(OH)₂-phenyl]; **BMC**=
 5 bismethoxycarbonylcaffeoyl = -COCH=CH-[3,4-(OM)₂-phenyl]. Components of procedures are abbreviated: [A]: ClCOOMe; [B]: Na₂CO₃; [C]: Ph₂CHN₂; [D]: HOAc; [E]: RCOCl; [F]: RCOCl/R₃N; [G]: L-tartaric acid; [H]: [COCl]₂; [I]: SOCl₂.

Fig 13 is a diagram of Scheme 4 showing the steps in the chemical synthesis of some of the compounds disclosed in the present invention. Abbreviations of
 10 compounds are as follows: **OM** = O-methoxycarbonyl = -OCOOMe; **DPM** = diphenylmethyl = -CHPh₂; **CAF** = caffeoyl = -COCH=CH-[3,4-(OH)₂-phenyl]; **BMC**= bismethoxycarbonylcaffeoyl = -COCH=CH-[3,4-(OM)₂-phenyl]. Components of procedures are abbreviated: [A]: ClCOOMe; [B]: Na₂CO₃; [C]: Ph₂CHN₂; [D]: HOAc; [E]: RCOCl; [F]: RCOCl/R₃N; [G]: L-tartaric acid; [H]: [COCl]₂; [I]: SOCl₂.

15 Fig 14 is a graph of HIV_{NL4-3} passaged in the presence (squares) or absence (circles) of increasing concentrations of L-chicoric acid. Each point is the mean of triplicate samples; bars are one standard deviation.

Fig. 15 is a schematic diagram of the cloning strategy used to analyze mutations in HIV IN.


20 Fig. 16a is a graph showing the relative resistance of 4 molecular clones of HIV to the RT inhibitor zidovudine.

Fig. 16b is a graph showing the relative resistance of 4 molecular clones of HIV to the IN inhibitor L-chicoric acid.

The invention and its various embodiments may now be understood by turning
 25 to the following Detailed Description of the Preferred Embodiments.

Detailed Description of the Preferred Embodiments

The present invention generally related to integrase inhibitors having the general structural formula (formula(I)):



wherein,

R_1 and R_3 are selected from hydrogen, OR_6 , NR_6 and aralkyl groups, optionally substituted with between one and three substituents selected from hydroxyl, halo, lower alkoxy, lower alkylcarbonyloxy and lower alkoxy carbonyloxy groups;

R and R_5 are selected from hydrogen, COOR_7 and CONHR_7 ;

R_2 and R_4 are hydrogen or may combine with each other to form a cycloalkyl ring or with R_1 and R_3 , respectively, to form aromatic rings optionally substituted with from one to three substituents selected from OR_6 and NR_6 groups;

R_6 is selected from



where,

X is a saturated or unsaturated, acyclic or cyclic, straight or branched, chiral or achiral hydrocarbyl group with from 0 to 10 carbon atoms, and

Y is selected from CH=CH, n=CH, CH=N, O, S, or NR₇, n is between 0 and 4, and m is between 0 and 3.


5 R₇ is selected from hydrogen, alkyl and aralkyl groups;

R₈ is selected from hydrogen, hydroxy, halo, lower alkoxy, lower alkylcarbonyloxy and lower alkoxyalkylcarbonyloxy or a cyclic carbonate group when the hydroxy groups are on adjacent carbons;

10 Additionally, when R and R₅ are COOR₇ or CONHR₇, the groups R₁, R₂ and R₃, R₄ may combine to form an arylidene group, optionally substituted from 1 to 3 substituents selected from hydroxy, halo, lower alkoxy, lower alkylcarbonyloxy and lower alkoxyalkylcarbonyloxy.

A preferred group of compounds of formula (I) is that wherein, R and R₅ are COOR₇ and CONR₇R₉; R₂ and R₄ are hydrogens; R₁ and R₃ are aralkyl or R₁, R₂ and
15 R₃, R₄ may combine to form an arylidene group, optionally substituted with up to 3 hydroxy, alkylcarbonyloxy or alkoxyalkylcarbonyloxy groups or OR₆ or NR₆; R₆ is

20



where, X is saturated or unsaturated hydrocarbyl group with from 0 to 4 carbon atoms, Y is CH=CH, CH=N, N=CH, O, S or NR₇; R₇ and R₉ are same or different and may be hydrogen, lower alkyl and alkenyl or aralkyl or R₇ and R₉ may combine to form a
25 heterocyclic ring, optionally substituted with one or more lower alkyl with from 1 to 5 carbon atoms, aralkyl and hydroxy groups; R₈ represents up to 3 hydroxy, alkylcarbonyloxy or alkoxyalkylcarbonyloxy groups and n is 0.

5 Examples include:

- 2,3-di-3-(3,4-dihydroxyphenyl)-2-propenoyl L-tartaric acid (*Dicaffeoyl-L-tartaric acid*)
 2,3-di-3-(3,4-dihydroxyphenyl)-2-propenoyl D-tartaric acid (*Dicaffeoyl-D-tartaric acid*)
 10 2,3-di-3-(3,4-dihydroxyphenyl)-2-propenoyl meso-tartaric acid (*Dicaffeoyl-meso-tartaric acid*)
 2,3-di-3-(3,4-dihydroxyphenyl)propanoyl L-tartaric acid [*Bis-2,3-(3,4-dihydroxydihydrocinnamoyl)-L-tartaric acid*]
 15 2,3-di-3,4-dihydroxybenzoyl L-tartaric acid [*Bis-(3,4-dihydroxybenzoyl) L-tartaric acid*]
 2,3-di-(3,4-dihydroxyphenyl)acetyl L-tartaric acid [*Bis-(3,4-dihydroxyphenylacetyl) L-tartaric acid*]
 2,3-di-3,4,5-trihydroxybenzoyl L-tartaric acid (*Digalloyl-L-tartaric acid*)
 20 2,3-di-2,3-dihydroxybenzoyl L-tartaric acid [*Bis-(2,3-dihydroxybenzoyl) L-tartaric acid*]
 2,3-di-3,4-dihydroxybenzylidene succinic acid (*di-3,4-dihydroxybenzylidene succinic acid*)
 2,3-di-3,4-dihydroxybenzyl succinic acid
 25 and esters and pharmaceutically acceptable salts thereof.

Yet another preferred group of compounds of formula (I) is that wherein, R,
 R₂, R₄ and R₅ are hydrogens or R₂ and R₄ may combine to form a cycloalkyl ring or
 with R₁ and R₂ may form an aromatic ring substituted with up to 3 OR₆ or NR₆
 30 groups; R₁ and R₃ are OR₆ or NR₆, where R₆, X, Y, R₈ and m are described as earlier
 and n is 0-4.

Examples include:

- 1,2-Dihydroxyethyl 3-(3,4-dihydroxyphenyl)-2-propenoate (*1,2-Dicaffeoylethanediol*)
 1,3-Dihydroxypropyl 3-(3,4-dihydroxyphenyl)-2-propenoate (*1,3-Dicaffeoylpropanediol*)
 1,4-Dihydroxybutyl 3-(3,4-dihydroxyphenyl)-2-propenoate (*1,4-Dicaffeoylbutanediol*)
 40 trans-1,4-Dihydroxycyclohexyl 3-(3,4-dihydroxyphenyl)-2-propenoate (*1,4-trans-Dicaffeoylcyclohexanediol*)

- cis-1,4-Dihydroxycyclohexyl 3-(3,4-dihydroxyphenyl)-2-propenoate (*1,4-cis-Dicaffeoylcyclohexanediol*)
 trans-1,3-Dihydroxycyclohexyl 3-(3,4-dihydroxyphenyl)-2-propenoate (*1,3-trans-Dicaffeoylcyclohexanediol*)
 5 cis-1,3-Dihydroxycyclohexyl 3-(3,4-dihydroxyphenyl)-2-propenoate (*1,3-cis-Dicaffeoylcyclohexanediol*)
 trans-1,2-Dihydroxycyclohexyl 3-(3,4-dihydroxyphenyl)-2-propenoate (*1,2-trans-Dicaffeoylcyclohexanediol*)
 10 cis-1,2-Dihydroxycyclohexyl 3-(3,4-dihydroxyphenyl)-2-propenoate (*1,2-cis-Dicaffeoylcyclohexanediol*)
 1-Carboxyphenyl-3,5-di-3-(3,4-dihydroxyphenyl)-2-propenoate (*3,5-Dicaffeoyl benzoic acid*)
 1-Carboxyphenyl-3,4-di-3-(3,4-dihydroxyphenyl)-2-propenoate (*bis-3,4-Dicaffeoyl benzoic acid*)
 15 1-Carboxyphenyl-3,4-di-3-(3,4-dihydroxyphenyl)-2-propenamide (*bis-3,4-Dicaffeoyl benzoic acid*)
 and esters and pharmaceutically acceptable salts thereof.

- Yet another preferred group of compounds of formula (I) is that wherein, R is
 20 COOR₇ and CONR₇R₈; R₁, R₄ and R₅ are hydrogens; R₂ and R₃ are OR₆ and NR₆; R₆, X, Y, R₇, R₈, R₉ and m are as defined earlier and n is 0-4.

Examples include:

- 25 1-Carboxy-2-[3-(3,4-dihydroxyphenyl)-2-propenoyl]amino- 3-propyl[3-(3,4-dihydroxyphenyl)-2-propenoate (*2,3-Dicaffeoyl-L-serine*)
 1-Carboxy-3-[3-(3,4-dihydroxyphenyl)-2-propenoylamino]- 2-propyl [3-(3,4-dihydroxyphenyl)-2-propenoate (*bis-Dicaffeoyl-L-isoserine*)
 2,3-Di-[3-(3,4-dihydroxyphenyl)-2-propenoyl]aminopropanoic acid (*2,3-Dicaffeoyldiamidopropionic acid*)
 30 1-Carboxypropyl di-2,3-[3-(3,4-dihydroxyphenyl)-2-propenoate] (*1,2-Dicaffeoyl-L-glyceric acid*)
 2,6-Di-[3-(3,4-dihydroxyphenyl)-2-propenoyl]aminohexanoic acid (*1,4-Dicaffeoyl-L-lysine*)
 35

It will be readily appreciated by those of skill in the art that certain compounds represented by the above formula may exhibit optical and geometric isomerism. However, when no designation of isomers is specified with respect to the compounds

of the present invention, it is to be understood that all possible stereoisomers (R, S), geometric isomers (E, Z) and racemates are included within the invention.

In addition, certain of the compounds that fall within the described bounds of the present invention may form salts with organic and inorganic bases, and it is specifically contemplated that all such salts, in particular physiologically acceptable salts, are included within the present invention.

The chemical structures of the compounds are illustrated in Figs. 1-4. In Fig. 1a, the D- and meso- isomers of L-chicoric acid are identical in this illustrative format. Pharmacological data about the compounds that constitute the invention can be found in Table 1. Table 1 lists the compounds by name, with a chemical identification number keyed to the drawings, LD₅, ED₅₀, and IC₅₀. The first compound in Table 1, L-chicoric acid, a previously described DCTA, is included for reference. LD₅, the 5% lethal dose, is a measure of the toxicity of compound to living, cultured cells. It is the concentration at which cell growth is inhibited by 5%. This represents a truly non-toxic dose as it is within one standard deviation of the growth observed for cells cultured in the absence of the compound. ED₅₀, the 50% effective dose, is the concentration of compound that inhibits HIV-induced cell death by 50% with respect to control HIV infections of cells monitored in the absence of compound. IC₅₀, the 50% inhibitory dose, is the concentration of compound that is observed to inhibit purified HIV IN activity *in vitro* in an assay of IN dependent disintegration. Most simply understood, disintegration is a term used to refer to the reverse of integration.

The biological role of IN is to catalyze the insertion of viral DNA into the double-stranded, nuclear DNA of a host cell, while leaving flanking free viral 5' ends. However, because IN is a true enzyme, it can also catalyze the reverse reaction, namely, excision of viral-like DNA from a double-stranded DNA substrate where free viral-like 5' ends occur. The use of an appropriately designed DNA substrate allows for IN dependent disintegration to be measured. Not all of the possible enzymatic functions of IN are completely understood; therefore, it is not warranted to state that

in vitro measurement of disintegration inhibition is a complete measure of IN inhibition. Nonetheless, the compounds presented herein generally show a strong correlation between *in vitro* potency as measured by inhibition of disintegration, and biological potency as measured by inhibition of HIV replication in living, cultured cells. Furthermore, for those compounds in which other measures of IN activity (3'-end processing and strand transfer) have been measured there has been a 1:1 correlation between inhibition of these steps and disintegration.

All of the compounds included in Table 1 inhibit HIV IN dependent disintegration by 90% or more when tested at 25 μ M concentration. This is an *in vitro* measure of potency. The IC_{50} is also a measure of *in vitro* potency. This value is significantly smaller than the LD_5 for all the compounds suggesting that each of the compounds may serve to inhibit HIV replication in cells through HIV IN inhibition at non-toxic concentrations. Biological potency can be more directly assessed by reference to the LD_5 and ED_{50} . In all cases, the ED_{50} is less than or equal to the LD_5 , thus, with these compounds a 50% effective dose is expected to cause little or no significant cell toxicity. In general, the wider the margin of LD_5 over ED_{50} , the greater the concentration of the compound that can be used without danger of causing cell death.

20

Table 1

Compound Name	ID number	LD_5 (μ M)	ED_{50} (μ M)	IC_{50} (μ M)
L-chicoric acid	1	264	4.2	0.18
D-chicoric acid	2	115	6.3	0.07
m-chicoric acid	3	373	4.2	0.08
1,2-dicaffeoyl-L-glyceric acid	19	145	2.3	0.520
Bis-(3,4-dihydroxydihydrocinnamoyl)-	22	>263	8.4	2.38

Compound Name	ID number	LD ₅ (μM)	ED ₅₀ (μM)	IC ₅₀ (μM)
L-tartaric acid				
Digalloyl-L-tartaric acid	25	2.7	0.66	0.97
Bis-(3,4-dihydroxybenzoyl)-L-tartaric acid	26	90	0.95	0.43
Bis-(3,4-dihydroxyphenylacetyl)-L-tartaric acid	28	70	35	0.88
2-3-dicaffeoyldiamidopropionic acid	35	50	70	0.570
Bis-3,4-dicaffeoyldiamidobenzoic acid	36	47	4.6	0.734
Di-3,4-dihydroxybenzylidene succinic acid	37	35	8.7	2.19
Di-3,4-dihydroxybenzylidene succinic acid	38	69	4.4	0.858
2,3-dicaffeoyl-L-serine	39	29	2.5	0.120
Bis-dicaffeoyl-L-isoserine	40	175	3.0	0.195
1,4-dicaffeoyl-L-lysine	41	29.2	3.7	2.23

Many of these compounds appear to selectively inhibit HIV IN as the means by which they inhibit HIV replication in living, cultured cells. This is most strongly indicated for compounds 1, 22, 25, 26, and 28 which all show reduced efficacy against a molecular clone of HIV, HIV_{NL4-3clone1-D4}, that was generated by selection for resistance to L-chicoric acid (compound 1) and was shown to bear a single point mutation in its gene for IN. The single point mutation results in the substitution of a serine amino-acid residue for the normally occurring glycine amino-acid residue at position 140 in the primary sequence of HIV IN. The demonstration that a single amino-acid substitution at this position within IN confers resistance to L-chicoric acid

is strong evidence that the principle target for the anti-HIV activity of L-chicoric acid is IN. Likewise, if this mutation confers marked resistance to other anti-HIV compounds the evidence is equally strong that IN is also a target of these compounds. Referring to Table 2 which shows the anti-HIV activity of L-chicoric acid analogues against the L-chicoric acid resistant clone, HIV-1_{NL4-3clone1-D4}, the ED₅₀ for each of the noted compounds is significantly increased when measured against the resistant molecular clone HIV_{NL4-3clone1-D4} as compared to against the parental non-resistant strain HIV_{NL4-3}.

Table 2

Compound	ED ₅₀ (in μ M)		Fold Change
	HIV _{NL4-3} ^a	HIV _{NL4-3clone1-D4} ^b	
1	0.78	61.25	78
22	7.8	31.25	4
25	0.29	31.25	107
26	0.82	52.5	64
28	15.6	62.5	4

^aThe anti-HIV activity of each compound was tested against the infectious molecular clone HIV-1_{NL4-3}. The ED₅₀ is expressed as the mean of triplicate infections.

^bThe anti-HIV activity of each compound was measured against L-chicoric acid-resistant molecular clone HIV-1_{NL4-3clone1-D4}. The results are expressed as the mean of triplicate infections.

Since combination drug therapies are now the standard of care in the medical treatment of HIV infection, any new therapeutics and therapeutic leads should work in combination with existing classes of anti-HIV drugs. The therapeutic effects of drugs, when used in combination, can generally be described as falling into one of three categories. In the best case, drugs administered in combination can act synergistically,

having net therapeutic effects that are greater than the sum of the effects observed when the drugs are administered individually. When drug combinations appear to act with equivalent net therapeutic effects as the sum of the effects when administered individually, the drugs are said to act additively. In the worst case, drugs can act
5 counter-productively, resulting in reduced efficacy when used in combination; this is referred to as antagonism. In general, for the use a drug combination to be warranted, additive to synergistic effects should be demonstrable. Demonstration of such effects in vitro is a first indication that such effects can occur in a medically prescribed therapeutic regimen. As noted, combinations of protease inhibitors and RT inhibitors
10 have previously demonstrated additive to synergistic anti-HIV effects in vitro, which have been similar to their in vivo effects. Similarly, now such anti-HIV activity has been demonstrated for established anti-HIV agents in conjunction with the lead IN inhibitor L-chicoric acid (L-CCA, compound 1). In almost all circumstances tested, L-chicoric acid has acted either synergistically or additively with RT inhibitors and/or
15 protease inhibitors to inhibit HIV replication.

Pairwise combinations of L-CCA with individual RT inhibitors or a protease inhibitor were tested in living cell assays against three different molecular clones of HIV. The molecular clones were HIV_{NL4-3 clone 7-1}, which has silent mutations in the gene for IN and shows an increased susceptibility to the RT inhibitor dideoxycytidine
20 (DDC), HIV_{NL4-3 M185V}, which has a methionine to valine mutation in the gene for RT and shows partial resistance to DDC and another RT inhibitor 2',3'-dideoxyinosine (DDI), and HIV_{NL4-3 JF26/A7}, which has numerous mutations in the gene for RT and is highly resistant to the RT inhibitor zidovudine (ZDV). For each of these HIV clones, the ED₅₀ was determined for the anti-HIV compounds ZDV, DDC, DDI, the protease
25 inhibitor (PI) Nelfinavir (provided by Agouron Pharmaceuticals, San Diego), and L-CCA. This is shown in Fig. 5. The results of mixed dose effect analyses using the method of Chou and Talalay (Adv. Enzyme Regu. 22:27-55(1984)) are summarized in Table 3 The quantitative data behind this summary is described in the detailed description of the preferred embodiments and in Tables 4-6 . Table 4 shows the data

for the DDC plus L-chicoric acid combination. Table 5 shows the results for Nelfinavir plus L-chicoric acid. While Table 6 shows the results for Zidovudine plus L-chicoric acid. The principle conclusion from these experiments is that in living cell assays of anti-HIV replication, L-CCA shows synergistic effects when paired with the RT inhibitor DDC and when paired with the protease inhibitor Nelfinavir, against all three molecular clones of HIV. L-CCA also shows synergism when paired with the RT inhibitor ZDV against two of the three HIV clones.

Table 3

Resistance	HIV	ZDV + L-CCA	DDC + L-CCA	L-CCA + PI
None	clone7-1	SI Ant	S	S
DDC	M184V	MS	SS	S
ZDV	JF26/A7	S	SS	MS

DDC = dideoxycytidine
ZDV = zidovudine
L-CCA = L-chicoric acid
PI = protease inhibitor (nelfinavir)
MS = moderate synergism: CI = 0.7-0.85
S = synergy CI = 0.3-0.7
SS = Strong Synergism: CI = 0.1-0.3
VSS = Very Strong Synergism: CI < 0.1
A = additivity: CI = 0.9-1.1
SI Ant = slight antagonism: CI = 1-2.0

Table 4

Virus (HIV-1)	Fa* (protection)	CI [†]	DDC (nM)	L-CCA (nM)
NL4-3 _{clone7-1}	0.2	1.144 (0.35)	12.4	148.3
	0.4	0.726 (0.18)	21.1	253.1
	0.6	0.578 (0.14)	32.8	393.7
	0.8	0.493 (0.13)	56.0	672.0

Virus (HIV-1)	Fa* (protection)	CI [†]	DDC (nM)	L-CCA (nM)
NL4-3 _{cloneM184V}	0.9	0.456 (0.14)	87.1	1046
	0.2	0.576 (0.27)	21.6	64.8
	0.4	0.358 (0.08)	43.2	129.7
	0.6	0.283 (0.05)	76.8	230.3
	0.8	0.249 (0.05)	153.7	461.2
NL4-3 _{cloneJF26/A7}	0.9	0.242 (0.06)	273	819
	0.2	2.367 (1.6)	13.0	78.1
	0.4	0.395 (0.1)	23.8	142.8
	0.6	0.214 (0.06)	39.2	235.3
	0.8	0.177 (0.05)	71.8	430.5
	0.9	0.165 (0.09)	118	709

*Fa is the fraction affected (i.e. Fa x 100 is the percent protection). Values for 20%, 40%, 60%, 80%, and 90% are indicated.

[†]Is the combination index. It was calculated using CalcuSyn for Windows and is one representative experiment from a minimum of three. Each experimental value

5

Table 5

Virus (HIV-1)	Fa* (protection)	CI [†]	Nelfinavir (nM)	L-CCA (nM)
NL4-3 _{clone7-1}	0.2	0.906 (0.29)	2.9	163.6
	0.4	0.472 (0.12)	4.9	279.6
	0.6	0.329 (0.08)	7.6	435.4
	0.8	0.26 (0.08)	13.1	743.9
	0.9	0.239 (0.09)	20.3	1158
NL4-3 _{cloneM184V}	0.2	1.81 (0.65)	2.5	144

Virus (HIV-1)	Fa* (protection)	CI [†]	Nelfinavir (nM)	L-CCA (nM)
NL4-3 _{cloneJF26/A7}	0.4	0.91 (0.21)	4.7	269.2
	0.6	0.536 (0.12)	7.9	451.5
	0.8	0.293 (0.08)	14.8	844.1
	0.9	0.183 (0.07)	24.8	1416
	0.2	7.982 (5.3)	4.6	264.5
	0.4	1.138 (0.25)	7.0	401.8
	0.6	0.577 (0.13)	10.0	567.8
	0.8	0.444 (0.11)	15.1	862.5
	0.9	0.388 (0.11)	21.3	1219

*Fa is the fraction affected (i.e. Fa x 100 is the percent protection). Values for 20%, 40%, 60%, 80%, and 90% are indicated.

[†]Is the combination index. It was calculated using CalcuSyn for Windows and is one representative experiment from a minimum of three. Each experimental value was determined in triplicate. Values in parenthesis are 1.96 x SD as estimated in the computer program.

5

Table 6

Virus (HIV-1)	Fa* (protection)	CI [†]	Zidovudine (nM)	L-CCA (nM)
NL4-3 _{clone7-1}	0.2	0.898 (0.37)	2.7	67.2
	0.4	1.023 (0.34)	8.7	217
	0.6	1.197 (0.34)	22.9	571.8
	0.8	1.508 (0.44)	73.8	1845
	0.9	1.865 (0.67)	194	4861
NL4-3 _{cloneM184V}	0.2	0.803 (0.39)	4.9	63.2
	0.4	0.508 (0.17)	10.2	132.7
	0.6	0.373 (0.1)	18.9	245.2

Virus (HIV-1)	Fa* (protection)	CI [†]	Zidovudine (nM)	L-CCA (nM)
	0.8	0.272 (0.07)	39.6	514.8
	0.9	0.217 (0.07)	73	951
NL4-3 _{cloneJF26/A7}	0.2	12.6 (8.9)	150.2	450.6
	0.4	1.119 (0.36)	259.8	779.4
	0.6	0.157 (0.08)	409	1226
	0.8	0.017 (0.04)	707	2120
	0.9	0.003 (0.02)	1112	3336

*Fa is the fraction affected (i.e. Fa x 100 is the percent protection). Values for 20%, 40%, 60%, 80%, and 90% are indicated.

[†]Is the combination index. It was calculated using CalcuSyn for Windows and is one representative experiment from a minimum of three. Each experimental value was determined in triplicate. Values in parenthesis are 1.96 x SD as estimated in the computer program.

A study has also been conducted that shows synergistic activity of L-CCA against HIV when included in a triple combination of anti-HIV agents. As shown in Fig. 6 against the tissue adapted strain of HIV, HIV_{LAI}, the addition of L-CCA to a combination of zidovudine and the protease inhibitor AG1350 (provided by Agouron Pharmaceuticals, San Diego), allowed the dosages of each of the established inhibitors to be reduced by 33% to achieve equivalent anti-HIV replication effects in living, cultured cells. Furthermore, as shown in Fig. 7, when all compounds were administered at constant dose, the triple combination of L-CCA plus zidovudine plus protease inhibitor showed greater anti-HIV_{LAI} replication potency than any of the compounds individually or in pairwise combination. Figs. 8 and 9 show that similar results were obtained against two clinically isolated HIV strains, HIV_{R45} and HIV_{R19}. Against both strains, a triple combination including L-CCA, zidovudine and protease inhibitor, had greater anti-HIV replication activity than a dual combination of ZDV

and protease inhibitor. The measurements that yielded these results are more completely described in the detailed description of the preferred embodiments.

The lead compound L-CCA has demonstrable compatibility and additive to synergistic effects with compounds from the established classes of anti-HIV agents.

- 5 The novel, analogue compounds of L-CCA presented generally show equivalent or improved anti-HIV effects consistent with similar potency and selectivity shown when evaluated individually. The translation of such *in vitro* synergistic effects to *in vivo* effects has already occurred with combinations of established anti-HIV compounds. The addition of this new class, as represented by the novel compounds introduced
- 10 here, of IN inhibitors with demonstrable anti-HIV replication activity provides a new avenue for the pursuit and development of clinically valuable anti-HIV therapeutics.

- Each novel compound was pursued using the following steps: 1) chemical synthesis, 2) chemical characterization, 3) biological characterization with living cells, including a) determination of LD₅ by cell toxicity assay, b) determination of ED₅₀ by
- 15 anti-HIV assay, and c) assessment of selectivity against IN by ED₅₀ determination against the L-chicoric acid (L-CCA) resistant strain, HIV_{NL4-3clone1-D4}, 4) biochemical characterization, i.e., determination of IC₅₀ with the disintegration assay, and 5) determination of pharmacological compatibility of anti-HIV activity when used in combination with members of the established classes of anti-HIV therapeutics, i.e.,
- 20 determination of capacity to act synergistically. This entire course of assessment is not presented for all compounds. Representative examples of these steps and relevant data illustrated by figures and tables are presented below.

Synthesis

- In an effort to develop more potent and selective inhibitors of HIV-1 IN,
- 25 analogues of the DCTA, L-CCA, were synthesized. Exemplary synthetic schemes for a few of these compounds are shown in Figs. 1-4 and described below. The length of the side chains, spatial arrangement of the phenolic hydroxyl groups, size and structure of the central molecular core structure, and number of free carboxyl groups

were all varied. The effects of these changes were assayed against HIV-1 IN in the disintegration reaction as well as against HIV-1 replication and cell growth in tissue culture.

5 The synthetic schemes which are illustrated in Figs. 10-13 are briefly described as follows:

L-(1), D-(2)- and meso-(3) DCTA were synthesized by acylation of the bis(diphenylmethyl) tartrates (1a, 2a and 3a) with the protected caffeoyl chloride (35a) to give the fully-blocked compounds (20, 2b and 3b) from which the phenol and carboxyl blocking groups were sequentially removed via (21, 2c and 3c) (Fig. 10,
10 Scheme 1).

A compound with a single carboxyl group, dicaffeoylglyceric acid (19) was prepared by acylation with (35a) and deprotection via 19a (Fig. 11, Scheme 2).

To determine the effect on bioactivity of the group linking the catechol and tartaric acid moieties of 1, analogues were prepared with the CH=CH replaced by two
15 (22), one (28) or zero (26) methylene groups. Direct acylation of L-tartaric acid with the acid chlorides of the phenol protected acids 22a, 28a and 26a gave 22b, 28b and 26b from which the phenol blocking groups were removed (Fig. 12, Scheme 3).

The significance for bioactivity of the number and position of the phenol groups was determined in the benzoic acid series (Fig. 13, Scheme 4). An analogue
20 with three (25) phenolic hydroxyl groups was synthesized by acylation of the diester of L-tartaric acid 1a with the acid chloride of the phenol-protected acid 25a followed by removal of the appropriate blocking groups.

Chemical Procedures:

Detailed synthetic procedures and chemical characterizations, as referred to in
25 Figs. 10-13, are described as follows.

General. All melting points were measured on a Mel-Temp apparatus and are corrected. Elemental analyses were performed by M-H-W laboratories of Phoenix, AZ. Mass spectrometry (MS) analyses were obtained on a HP-5989A instrument at 70 eV in the EI mode with GC sampling unless otherwise noted as DIP (direct insertion probe). Selected peaks are reported as m/z (rel.int.) including all (except isotope peaks) with $m/z > 100$ and relative intensity > 25 . HRFABMS were performed at the Washington University Resource for Biomedical and Bio-Organic Mass Spectrometry, St. Louis, MO. NMR spectra were obtained on a Varian XL-300 instrument at 299.936 (^1H) or 75.427 (^{13}C) unless otherwise noted in the indicated solvent (D=DMSO- d_6 , C= CDCl_3 , M= CD_3OD) and are reported in order as: ppm downfield from TMS at $\delta=0$, multiplicity (s, d, dd, m, bs), observed couplings J in Hz and relative # of H's. APT spectra results are expressed as $d=\text{C}$ or CH_2 , $u=\text{CH}$ or CH_3 . HPLC used a C-18-10 μm , 250mm \times 4.6mm analytical column or a C18-10 μm , 250 \times 22mm preparative column eluted with either methanol-water or acetonitrile-water mixtures containing 1% acetic acid with UV detection at 254 nm. The following general synthetic procedures refer to both Schemes 1-4 and the description of the preparation of the specific compounds that follows. No attempt was made to optimize yields.

Procedure A, Carboxymethylation of Phenols: A solution of the phenolic acid in 2.2 eq 1N NaOH was cooled to 0°C and 3.5 eq methyl chloroformate was added drop-wise with stirring. The precipitate was collected by filtration, washed with deionized water, air dried and recrystallized to give the blocked phenolic acid.

Procedure B, Removal of Carboxymethyl Groups: The carboxymethylated phenol was dissolved in tetrahydrofuran (THF) and hydrolyzed with 2% Na_2CO_3 with enough methanol for homogeneity at room temperature, under N_2 for 5-7hr. The reaction mixture was acidified to pH=1-2 with 10N HCl, extracted with ether, the ether evaporated and the residue purified by chromatography on silica gel, if necessary.

Procedure C, Formation of Diphenylmethyl Esters: A solution of 1.25eq diphenyldiazomethane per COOH group in chloroform was added to the carboxylic acid in MeOH-CHCl₃. The mixture was stirred at room temperature until the red color disappeared, washed successively with 1N HCl, saturated NaHCO₃ and H₂O. The organic layer was dried with Na₂SO₄ and evaporated on a Rotovap to afford the diphenylmethyl ester which was recrystallized if necessary.

Procedure D, Hydrolysis of Diphenylmethyl Esters: The diphenylmethyl esters were deprotected in refluxing 70% acetic acid under N₂ for 4 hours. The solvent was removed by lyophilization and the residue purified by chromatography on Sephadex LH-20.

Procedure E, Direct Acylation of Alcohol Groups: The alcohol was reacted with a slight excess of the acid chloride without solvent in an oil bath at 130-140 °C for 15 min and the residue chromatographed on silica gel.

Procedure F, Solution Acylation of Alcohol Groups: The acyl chloride was reacted with the alcohol in anhydrous benzene with pyridine or triethylamine as a catalyst for 2.5hr at room temperature. The reaction mixture was successively washed with 1N HCl, saturated NaHCO₃ and water and the organic layer evaporated to give the ester which was purified on a silica gel column.

Procedure G, Direct Acylation of L-Tartaric Acid: A modification of Scarpati's method (*Tetrahedron* 4:43-48 (1958)) involves heating L-tartaric acid with an excess of an acyl chloride in an oil bath at 135-160°C for 10-30min followed by hydrolysis of the intermediate anhydride with 80% HOAc on a steam bath for 30 min. The residue from removal of the solvent below 40°C under reduced pressure was partitioned between water and ether and the latter dried and evaporated to give a crude product which was purified by chromatography on silica gel or Sephadex LH-20.

Procedure H, Formation of Acyl Chlorides with Oxalyl Chloride: A solution of the acid in excess oxalyl chloride was stirred with a 25-fold excess of

oxalyl chloride at room temperature for one hour, the excess reagent removed on a Rotovap and the acid chloride used immediately without purification.

Procedure I, Formation of Acyl Chlorides with Thionyl Chloride: A

5 solution of the acid in excess thionyl chloride was heated (NaOH trap) in an oil bath at 80-90°C until HCl evolution ceased. Removal of the thionyl chloride on a Rotovap gave the acid chloride used immediately without purification.

Specific Syntheses and Chemical Characterizations:

Dicaffeoyl-L-tartaric acid (L-chicoric acid, L-DTCA or L-CCA) (1). L-Tartaric acid was converted by Procedure C to **bis(diphenylmethyl) L-tartrate (1a)** as a white powder, mp=107-108°C; ¹H NMR (C): 7.24-7.32 (m, 20H), 6.98 (s, 2H), 4.75 (s, 2H); ¹³C (C): 170.7, 139.0, 138.9, 128.6, 128.5, 128.4, 128.1, 127.6, 126.9, 79.2, 72.3; DIP/MS: 315 (2), 183 (33), 167 (100), 165 (43). Reaction of **1a** with **35a** via Procedure F gave **bis(diphenylmethyl) bis[di(methoxycarbonyl)caffeoyl]-L-tartrate (20)**, mp=62-64°C; ¹H NMR (C): 7.50 (d, 16.0, 2H), 7.10-7.38 (m, 20H), 6.94 (s, 2H), 6.16 (d, 16.0, 2H), 6.04 (s, 2H), 3.93 (s, 6H), 3.92 (s, 6H); ¹³C (C): 164.8 (x2), 153.1, 152.9, 144.3, 143.9, 142.7, 138.8, 138.7, 133.0, 128.63, 128.57, 128.2 (x2), 127.3, 127.0 (x2), 123.50, 122.6, 117.5, 79.1, 71.1, 56.0 (x2). Removal of the methoxycarbonyl groups by Procedure B gave **bis(diphenylmethyl) dicaffeoyl-L-tartrate (21)**, mp=135-136°C (dec.); ¹H NMR (M): 7.47 (d, 15.8, 2H), 6.91 (s, 2H), 6.79-7.36 (m, 20H), 6.10 (s, 2H), 6.07 (d, 15.8, 2H); ¹³C (M): 167.4d, 166.8d, 150.2d, 148.8u, 146.9d, 140.7d (x2), 129.7u (x2), 129.2u (x2), 128.2u, 128.0u, 127.5d, 123.6u, 116.6u, 115.4u, 113.3u, 80.3u, 72.5u. Removal of the diphenylmethyl groups by Procedure D gave **L-DCTA (1)**, whose ¹H and ¹³C NMR agreed with the literature.

Dicaffeoyl-D-tartaric acid (D-chicoric acid, D-DCTA) (2). D-Tartaric acid was converted by Procedure C to **bis(diphenylmethyl) D-tartrate (2a)** as a white powder, mp=108-110°C; ¹H NMR (C): 7.28-7.34 (m, 20H), 6.99 (s, 2H), 4.76 (s, 2H); ¹³C (C): 170.7, 139.0, 138.9, 128.6, 128.5, 128.4, 128.1, 127.6, 126.9, 79.2, 72.3; DIP/MS: 315 (2), 183 (37), 167 (100), 165 (47). Reaction of **2a** with **35a** via

Procedure F gave **bis(diphenylmethyl) bis[di(methoxycarbonyl)caffeoyl]-D-tartrate (2b)** mp=61-63°C; ¹H NMR (C): 7.50 (d, 16.0, 2H), 7.09-7.37 (m, 20H), 6.94 (s, 2H), 6.16 (d, 16.0, 2H), 6.04 (s, 2H), 3.93 (s, 6H), 3.92 (s, 6H); ¹³C (C): 164.8 (x2), 153.1, 152.9, 144.3, 143.9, 142.7, 138.8, 138.7, 133.0, 128.63, 128.57, 128.2 (x2), 127.3, 127.0 (x2), 123.50, 122.6, 117.5, 79.1, 71.1, 56.0 (x2). Removal of the methoxycarbonyl groups by Procedure B gave **bis(diphenylmethyl) dicaffeoyl-D-tartrate (2c)**, mp=134-136°C (dec.); ¹H NMR (M): 7.49 (d, 15.8, 2H), 6.90 (s, 2H), 6.80-7.33 (m, 20H), 6.08 (s, 2H), 6.07 (d, 15.8, 2H); ¹³C (M): 167.4d, 166.8d, 150.0d, 148.7u, 146.8d, 140.6d, 140.5d, 129.6u (x2), 129.1u (x2), 128.1u, 127.9u, 127.4d, 123.6u, 116.5u, 115.3u, 113.2u, 80.4u, 72.5u. Removal of the diphenylmethyl groups by Procedure D gave **D-DCTA (2)**, whose ¹H and ¹³C NMR agreed with the literature.

Dicaffeoyl-meso-tartaric acid (meso-chicoric acid, meso-DCTA) (3). meso-Tartaric acid was converted by Procedure C to **bis(diphenylmethyl) meso-tartrate (3a)** as a white powder, mp=108-109°C; ¹H NMR (C): 7.18-7.27 (m, 20H), 6.82 (s, 2H), 4.72 (s, 2H); ¹³C (C): 170.2, 139.0, 138.7, 128.52, 128.45, 128.23, 128.18, 128.0, 127.2, 79.4, 73.1; DIP/MS: 315 (2), 183 (37), 167 (100), 165 (47); DIP/MS: 315 (2), 183 (35), 167 (100), 165 (48). Reaction of **3a** with **35a** via Procedure F gave **bis(diphenylmethyl) bis[di(methoxycarbonyl)caffeoyl]-meso-tartrate (3b)** mp=72-74°C; ¹H NMR (C): 7.59 (d, 16.0, 2H), 7.21-7.38 (m, 20H), 6.88 (s, 2H), 6.29 (d, 16.0, 2H), 6.02 (s, 2H), 3.91 (s, 6H), 3.90 (s, 6H); ¹³C (C): 164.9, 164.8, 153.0, 152.9, 144.6, 143.9, 142.7, 139.01, 138.98, 133.01, 128.6, 128.5, 128.27, 128.1, 127.3, 127.1(x2), 123.5, 122.6, 117.8, 79.6, 71.6, 55.9 (x2). Removal of the methoxycarbonyl groups by Procedure B gave **bis(diphenylmethyl) dicaffeoyl-meso-tartrate (3c)**, mp=142-4°C (dec.); ¹H NMR (M): 7.55 (d, 16.0, 2H), 6.82 (s, 2H), 6.77-7.25 (m, 20H), 6.20 (d, 16.0, 2H), 6.01 (s, 2H); ¹³C (M): 167.4d, 166.8d, 150.1d, 148.9u, 146.8d, 140.8 (x2)d, 129.6u, 129.5u, 129.2u, 129.1u, 128.2u, 128.1u, 127.3d, 123.5u, 116.5u, 115.4u, 113.4u, 80.8u, 72.8u. Removal of the diphenylmethyl groups by Procedure D gave **meso-DCTA (3)** whose ¹H and ¹³C NMR agreed with the literature except that C-1 and C-2 of the tartaric acid portion were 3.5 upfield from that of an alleged meso-

chicoric acid from *Equisetum arvense*. Since the latter was isolated by chromatography with 1% NH₃ in MeOH, it may have been the ammonium salt. Dissociation of a carboxyl group deshields both the carbonyl and α -carbon resonances by 3-4ppm. This hypothesis was confirmed since the ¹³C-NMR of the ammonium salt of **3** matched that of the "meso chicoric acid" isolated from *Equisetum* which therefore was of the corresponding ammonium salt.

Dicafeoyl-L-glyceric acid (19). Calcium L-glycerate dihydrate (Aldrich 37241-2) was dried to constant weight and reacted with **35a** by Procedure E to give **bis[di(methoxycarbonyl)cafeoyl]glyceric acid (19a)**, gum; ¹H NMR (C): 7.73 (d, 16.0, 1H), 7.66 (d, 16.0, 1H), 7.3-7.5 (m, 6H), 6.51 (d, 16.0, 1H), 6.44 (d, 16.0, 1H), 5.56 (m, 1H), 4.6-4.8 (m, 2H), 3.92 (s, 12H); ¹³CNMR (C): 171.9, 165.9, 165.4, 153.1, 153.0, 152.9 (x2), 144.6 (x2), 143.83 (x2), 143.79, 142.7, 133.2, 133.1, 126.90, 126.85, 123.5 (x2), 122.6, 122.5, 118.5, 117.9, 70.2, 62.9, 56.0 (x4). Hydrolysis of **19a** by Procedure B but with a reaction time of only 10 min. gave **19**, mp 234-236°C; Anal. (C₂₁H₁₈O₁₀) C, H; ¹H NMR (D): 7.54 (d, 15.9, 1H), 7.51 (d, 15.9, 1H), 7.0-7.1 (m, 4H), 6.78 (dd, 1.6, 8.1, 2H), 6.37 (d, 15.9, 1H), 6.29 (d, 15.9, 1H), 5.36 (m, 1H), 4.56 (m, 2H); ¹³C (D): 168.5, 166.0, 165.6, 148.6, 148.5, 146.4, 146.0 (x2), 145.5, 125.2 (x2), 121.5, 121.4, 115.7 (x2), 115.0, 114.9, 113.0, 112.8, 70.2, 62.4.

Bis(3,4-dihydroxydihydrocinnamoyl)-L-tartaric acid (22). 3,4-Dihydroxydihydrocinnamic acid was reacted by Procedure A to give a mixture of **3,4-dimethoxycarbonyldihydrocinnamic acid (22a)** and its anhydride which were separated by silica gel column chromatography and the latter hydrolyzed by 80% HOAC solution on a steam bath to give **(22a)**: gum, ¹H NMR (C): 7.16 (d, 7.2, 1H), 7.14 (s, 1H), 7.10 (d, 7.2, 1H), 3.90 (s, 6H), 2.97 (t, 8.0, 2H), 2.69 (t, 8.1, 2H); ¹³C NMR (C): 177.5, 153.4 (x2), 142.2, 140.8, 139.4, 126.7, 123.0, 122.9, 55.8 (x2), 35.0, 29.9. Reaction of **22a** by Procedure I gave the acid chloride which was subjected to Procedure G to give **bis(3,4-dimethoxycarbonyldihydrocinnamoyl)-L-tartaric acid (22b)**: gum, ¹H NMR (C): 7.18 (d, 8.1, 2H), 7.10 (dd, 8.1, 1.9, 2H), 7.09 (d, 1.9, 2H), 5.55 (s, 2H), 3.92 (s, 6H), 3.91 (s, 6H), 2.98 (m, 4H), 2.81 (m, 4H); ¹³ NMR (C):

171.0, 167.1, 154.7, 153.7, 142.0, 140.5, 139.3, 127.0, 123.2, 123.0, 70.3, 56.1, 56.0, 34.6, 30.1. Deprotection of **22b** by Procedure B and preparative HPLC gave **22**, as a gum which on analytical HPLC gave a single peak with a retention time of 2.5' (70% MeOH-H₂O+1% HOAc) or 3.1' (45% MeCN-H₂O +1% HOAc); ¹H NMR (D): 6.66 (bs, 2H), 6.54 (d, 8.0, 2H), 6.35 (bd, 7.5, 2H), 5.38 (s, 2H), 2.75 (m, 4H), 2.49 (m, 4H); ¹³C NMR (D): 172.2, 170.8, 145.5, 143.5, 131.4, 118.5, 115.6, 115.5, 74.8, 35.3, 29.5; HRFABMS: Calcd. *m/z* for C₂₂H₂₂O₁₂Na, 501.1009; Fd. 501.1006.

Digalloyl-L-tartaric acid (25). Gallic acid (3,4,5-trihydroxybenzoic acid) was reacted by Procedure A to give **3,4,5-trimethoxycarbonylbenzoic acid (25a)** m.p.=143-144°C; ¹HNMR (C): 7.99 (s, 2H), 3.94 (s, 6H), 3.93 (s, 3H); ¹³CNMR (C): 169.1, 152.6, 151.6, 143.8, 139.1, 127.8, 122.6, 56.4, 56.2. Procedure I converted **25a** to the acid chloride which reacted with bis(diphenylmethyl) L-tartrate (**1a**) according to Procedure F to give **bis(diphenylmethyl) bis(3,4,5-trimethoxycarbonylbenzoyl) L-tartrate (25b)**, gum: ¹H NMR (C): 7.62 (s, 4H), 7.30-7.36 (m, 20H), 6.96 (s, 2H), 6.08 (s, 2H), 3.94 (s, 6H), 3.92 (s, 12H); ¹³CNMR (C): 164.0, 162.5, 152.4, 151.5, 143.6, 138.4, 138.1, 128.6, 128.54, 128.50, 128.3, 128.2, 127.5, 126.8, 126.5, 122.3, 79.3, 71.6, 56.4, 56.1. Sequential deprotection of **25b** by Procedures D and B and preparative HPLC gave **25**, as a gum which on analytical HPLC gave a single dominant peak with a retention time of 1.7'(10% MeOH-water+1% HOAc) or 4.8', (10% MeCN-H₂O +1% HOAc); ¹H NMR (D): 7.01 (s, 4H), 5.70 (s, 2H); ¹³C NMR (D): 167.3, 164.8, 117.8, 108.8, 145.5, 139.1, 70.9; HRFABMS: Calcd. *m/z* for C₁₈H₁₄O₁₄Na, 477.0281; Fd. 477.0276.

Bis(3,4-dihydroxybenzoyl)-L-tartaric acid (26). 3,4-Dihydroxybenzoic acid (Aldrich 10,980-0) was reacted by Procedure A to give **3,4-dimethoxycarbonylbenzoic acid (26a)** as an off-white solid, m.p.=168-169°C; ¹H NMR (C+M): 8.00 (dd, 8.6, 2.2, 1H), 7.99 (s, 1H), 7.39 (d, 8.6, 1H), 3.93 (s, 6H); ¹³C NMR (C+M): 167.0, 153.3, 153.0, 146.1, 142.3, 129.7, 128.8, 125.0, 123.1, 56.1 (x2). Procedure I converted **26a** to the acid chloride which reacted by Procedure G to give **bis(3,4-dimethoxycarbonylbenzoyl)-L-tartaric acid (26b)**, gum; ¹H NMR (C+M): 8.04 (dd,

8.4, 1.9, 2H), 8.07 (bs, 2H), 7.46 (d, 8.4, 2H), 6.00 (s, 2H), 5.78 (bs, 2H), 3.93 (s, 3H), 3.92 (s, 3H); ^{13}C NMR (C+M): 167.5, 163.5, 152.7, 152.4, 146.3, 142.0, 128.5, 127.4, 124.6, 123.0, 71.8, 55.6 (x2). Deprotection of **26b** by Procedure B and preparative HPLC gave **26** as a white solid, mp=175-176°C, Anal. ($\text{C}_{18}\text{H}_{14}\text{O}_{12}+1.5\text{H}_2\text{O}$) C, H; ^1H NMR (D): 9.97 (s, 2H), 9.56 (s, 2H), 7.41 (d, 2.5, 2H), 7.39 (d, 8.1, 2H), 6.87 (dd, 8.1, 2.5, 1H), 5.73 (d, 2.7, 2H); ^{13}C NMR (D): 167.4, 164.5, 151.1, 145.1, 122.3, 119.1, 116.4, 115.4, 71.0.

Bis(3,4-dihydroxyphenylacetyl)-L-tartaric acid (28). 3,4-Dihydroxyphenylacetic acid was reacted by Procedure A to give **3,4-dimethoxycarbonylphenylacetic acid (28a)**; oil; ^1H NMR (C): 7.28-7.17 (m, 3H), 3.89 (s, 6H), 3.63 (s, 2H); ^{13}C NMR (C): 175.7, 153.2 (x2), 142.1, 141.5, 132.5, 127.9, 124.0, 123.0, 55.8 (x2), 40.1. Reaction of **28a** by Procedure H gave the acid chloride which was subjected to Procedure G to give **bis(3,4-dimethoxycarbonylphenylacetyl)-L-tartaric acid (28b)**, gum; ^1H NMR (M): 7.35-7.20 (m, 3H), 5.72 (s, H-2), 3.85 (s, 6H), 3.80 (s, 2H); ^{13}C NMR (M): 171.3, 168.9, 154.74, 154.69, 143.6, 143.0, 134.2, 129.1, 125.3, 124.1, 72.7, 56.4 (x2), 40.3. Deprotection of **28b** by Procedure B and preparative HPLC gave **28** as a gum; Anal. ($\text{C}_{20}\text{H}_{18}\text{O}_{12}+\text{H}_2\text{O}$), calcd, C, 51.3, H, 4.3; found, C, 51.5, H, 4.8; Analytical HPLC gave a single major peak with a retention time of 2.72' (10:1 MeCN:H₂O +1% HOAc) or 1.76' (5:1 MeOH:H₂O); ^1H NMR (M): 6.72-6.68 (m, 4H), 6.59 (dd, 8.0, 1.9, 2H), 5.65 (s, 2H), 3.59 (s, 4H); ^{13}C NMR (M): 172.6, 169.1, 146.2, 145.5, 126.2, 121.9, 117.6, 116.3, 72.4, 40.6.

Biochemical Characterization

Following synthesis and chemical characterization, all compounds were evaluated for capacity to inhibit IN activity in vitro, in the absence of cells, in the disintegration assay. All IC_{50} values referred to and reported in Table 1 were determined with this assay.

Disintegration Assay.

The disintegration activities of IN in the presence and absence of inhibitors was assayed *in vitro* as modified from the method of Chow (*Science* 255:723-726 (1992)). The following oligonucleotides (GenoSys, Inc) were used as DNA substrates:

T1 (16 mer): 5'-CAGCAACGCAAGCTTG-3';

5 T3 (30 mer): 5'-GTCGACCTGCAGCCCAAGCTTGCGTTGCTG-3';

V2 (21mer): 5'-ACTGCTAGAGATTTTCCACAT-3';

V1/T2 (33 mer): 5'-
ATGTGGAAAATCTCTAGCAGGCTGCAGGTCGAC-3'.

10 The oligonucleotides were gel purified by the manufacturer. Oligonucleotide T1 was labeled at the 5'-end using T4 polynucleotide kinase and [γ - 32 P] ATP (3000 Ci/mmol, Amersham). The substrate for assaying disintegration activity, the Y-oligomer, was prepared by annealing the labeled T1 strand with oligonucleotides T3, V2, and V1/T2. In a 20 μ l volume, the DNA substrate (0.1 pmol) was incubated with
15 1.5 pmol recombinant IN for 60 minutes at 37°C in a buffer containing a final concentration of 20 mM HEPES pH 7.5, 10 mM DTT, 0.05% Nonidet P-40, and 10 mM MnCl_2 . To each 19 μ l of reaction mixture, 1 μ l of inhibitor at various concentrations in solvent or solvent alone was added. The reaction was stopped by the addition of EDTA to a final 18 mM concentration. Reaction products were heated at
20 90°C for 3 minutes before analysis by electrophoresis on a 15% polyacrylamide gel with 7M urea in Tris-borate-EDTA buffer. All reactions were performed at enzyme excess and reactions were stopped within the linear range of the reaction. Although it has been suggested by one group that the inhibitory effects of bis-catechols are metal ion dependent, all reactions were performed in the presence of MnCl_2 rather than
25 MgCl_2 . Our findings indicate that the DCTA's and DCQA's inhibit HIV IN whether Mg^{++} or Mn^{++} is the source of divalent cation and recent work from our groups suggests that metal ion is not required at all. These data are more consistent with the

inhibitory activity of bis-catechols against avian sarcoma virus IN. All compounds were first tested at 25 μ M. For active compounds, IC₅₀ analysis was determined from a median effect plot using CalcuSyn software (Biosoft, Cambridge, UK) on 0.5 log₁₀ dilutions of inhibitor in triplicate experiments.

5 **Selectivity Against IN of Compounds 1, 22, 25, 26 and 28**

As shown in Table 2, compounds 1, 22, 25, 26 and 28 demonstrated selectivity against IN when tested against two different molecular clones of HIV. The derivation of these clones and the manner in which this comparison was made is as follows.

Generation of L-chicoric acid resistant strain HIV_{NL4-3clone1-D4}

10 HIV_{NL4-3} plasmid (a gift from Dr. P. Krogstad, UCLA, Los Angeles, CA), was transfected in HeLa cells using Lipofectin® (Gibco/BRL). Excess DNA was removed by washing and cells were co-cultured with H9 cells for 18 hours. The H9 cells were removed and re-cultured in growth medium. When the culture was 100% positive for HIV antigens by indirect immunofluorescence, the virus was inoculated onto H9 cells
15 and incubated at 37°C for several weeks in the presence of 2 μ M L-chicoric acid. When this culture was 100% positive the virus was isolated and one aliquot was passaged in a similar manner in 4 μ M L-chicoric acid. Finally, virus was cultured in the presence of 8 μ M L-chicoric acid and the resultant virus filter-clarified, aliquoted, and stored at -70°C.

20 HIV_{NL4-3}, following culture in 8 μ M L-chicoric acid, was tested for resistance to the anti-HIV activity of the compound using a cytopathicity-based first described by Montefiori et al. This assay takes advantage of the lytic nature of T-cell tropic clones of HIV and decreased cell viability in this assay has been shown to correlate well with HIV replication. The fifty-percent effective dose (ED₅₀) of L-chicoric acid
25 against HIV_{NL4-3} control virus was 400 nM while HIV_{NL4-3} passaged in the presence of 8 μ M L-chicoric acid was completely resistant to the compound (Figure 14). Cloning and sequencing of virus from the HIV_{NL4-3} passaged in the presence of 8 μ M L-

chicoric acid was undertaken to determine the molecular basis for resistance to L-chicoric acid and to isolate a resistant HIV clone.

The overall cloning and sequencing strategy is illustrated in Figure 15. For cloning and sequencing, HIV from 10 ml of culture was centrifuged at 33,000 x g for 4 hours at 4°C. Virions were lysed and RNA isolated using Purescript® (Gentra, Frederick, MD). Primers used to amplify cDNA under these conditions recognize the 5' and 3' ends of IN at nucleotide positions 3580-3605 ("INS" primer: 5'-ggctctccgcggaatcaggaaagtag-3') and 4497-4522 ("INX" primer: 5'-gcttttctagaaatatacatatggtg-3') respectively, and generate a 943 base pair (bp) product.

10 First strand synthesis using INX primer and Superscript II®, an avian myeloblastosis virus RT (Gibco/BRL), was performed at 42°C for 50 minutes according to manufacturer's instructions. Thirty-eight cycle amplification was performed using *Pfu* thermostable DNA polymerase (Stratagene, La Jolla, CA) according to manufacturer's instructions. Optimum Mg⁺⁺ concentration for these studies was determined to be

15 1mM. Conditions for polymerase chain reaction were: 96°C for one minute, 40°C for 30 seconds, 72°C for 2 minutes for the first two cycles followed by 96°C for one minute, 55°C for one minute and 72°C for 3 minutes for thirty-six cycles. The final cycle included a 10-minute, 70°C elongation step. The resulting reverse transcriptase polymerase chain reaction (RT-PCR) products were separated by agarose gel

20 electrophoresis and visualized by ethidium bromide staining. Appropriately sized products were eluted from the gel and blunt-end ligated into PCRScript® (Stratagene) for dideoxynucleotide sequencing using Sequenase II® (US Biochemical, Cleveland, OH) according to manufacturer's instructions. The entire integrase sequence was determined through the use of six oligonucleotide primers: INS, INX, Core 1, 5'-cagctgtgataaatgtcagcta-3' (nt3721-3741), Core 2: 5'-ccattgtactgtctttaa-3' (nt4122-4142), INSPF: 5'-gcaatttcaccagtactacagt-3' (nt3962-3983), and INSPR: 5'-gtaggggaatgccaaattcctg-3' (nt4016-4036). Manual sequence analysis was confirmed by automated DNA sequencing.

Sequencing the integrase genes from both drug-resistant and control HIV_{NL4-3} demonstrated several mutations. Control virus contained two silent mutations at nucleotides 3832 and 4009. These silent mutations are believed to arise from a discrepancy in the published sequences of HIV_{NL4-3} and were likely not a result of passage of HIV in the absence of inhibitor. Drug-resistant HIV_{NL4-3} had the same silent mutations as well as a single G to A transition at nucleotide position 4025 leading to an amino acid change from glycine to serine at amino acid 140.

To determine whether this amino acid change was responsible for the observed resistant phenotype, the integrase genes from drug-resistant HIV_{NL4-3} were cloned into the native HIV_{NL4-3} plasmid (pNL4-3). This cloning was accomplished through site-directed mutagenesis introducing several silent mutations immediately upstream and downstream of the integrase gene. These mutations generated two unique restriction sites: an upstream *SacII* and a downstream *XbaI* (Fig. 15). Introduction of these mutations allowed the entire integrase gene with only minimal upstream and downstream nucleotides to be digested and "swapped" between drug-resistant and drug-sensitive clones. Two clones, 7-1 and 7-3, containing control integrase genes, wildtype except for silent mutations generating the restriction sites, and Clone 1-D4, containing drug-selected integrase with the G140S mutation were chosen for further study. Once transfected into HeLa cells and amplified in H9 cells, the viruses from all three clones maintained the same sensitivity to zidovudine, a reverse transcriptase inhibitor, as the parental HIV_{NL4-3} (Fig. 16a). The three clones containing wild-type integrase (the control viruses, clones 7-1 and 7-3 and wild-type HIV_{NL4-3}) maintained the L-chicoric acid-sensitive phenotype. Clone 1-D4, on the other hand, was resistant to the anti-HIV effects of L-chicoric acid (Figure 16b). The ED₅₀ for the drug-resistant clone was >600-fold higher than the drug-sensitive clones.

Amino acid 140 of integrase has not been mutated previously using site-directed mutagenesis. Furthermore, a search of the GenBank database does not indicate any naturally occurring mutations at this site. This amino acid is also highly conserved in integrases from other retroviruses, retrotransposons, and transposable

elements of bacteria. Mutation at this site, from the highly conserved glycine to serine, has little effect on HIV replication but completely abrogates the anti-HIV activity of L-chicoric acid.

Assays, as described above, to determine the ED_{50} for a given compound
5 against the molecular clone HIV_{NL4-3clone1-D4} and the parental clone HIV_{NL4-3} give an indication of the selectivity of the compound for inhibition of HIV replication through IN. Resistance to a compound, as measured by an increased ED_{50} , by clone HIV_{NL4-3clone1-D4}, implies selectivity of the compound for IN. Thus clone HIV_{NL4-3clone1-D4} can be used to screen candidate IN inhibitors for selectivity.

10 **Assessing Capacity of L-CCA to act Synergistically**

Dual Antiviral Agent Measurements

Molecular clones of HIV included wild-type HIV_{NL4-3}, HIV_{NL4-3 M184V}, and HIV_{NL4-3 JF26/A7}. All three clones were a generous gift from P. Krogstad (UCLA, Los Angeles, CA). Viruses were initially transfected in adherent HeLa cells using
15 Lipofectin®. After 48 hours, H9 cells were added. Following 24 hours of co-culture, non-adherent cells were removed and cultured. Cells were monitored by indirect immunofluorescence and RT release as described below until the culture was 100% infected by HIV-1. Supernatant fluids were collected and clarified of cells by low-speed centrifugation followed by filtration through 0.45 µm filters.

20 **RT assay and immunofluorescence analysis.**

Each culture supernatant was precipitated with 0.42 ml of 30% polyethylene glycol as described previously by Robinson et al. (*J. Acquired Immune Defic. Syndr.* 2: 33-42 (1989)). Precipitated virus was lysed and incorporation of [³H]-thymidine into poly rA-oligo dT templates was measured according to a modification by
25 Robinson (ibid.) of the method first described by Poiesz et al (*Proc. Natl. Acad. Sci. USA.* 77: 7415-7419 (1980)). Trichloroacetic acid precipitable raw cpm were

determined on a Beckman β -scintillation counter. The mean cpm for the triplicate infections was determined and mean background cpm from three cell control cultures run in parallel to each assay were subtracted. The resultant corrected cpm were multiplied by 8 to convert to cpm/ml of culture supernatant fluid. For

5 immunofluorescence analysis, cells from triplicate wells were combined and spotted onto glass slides. The percentage of cells expressing HIV antigens was quantitated using pooled human anti-HIV serum followed by fluorescein-conjugated goat anti-human IgG and observation under fluorescence microscopy as described by Robinson (ibid.).

10 Synergy Analysis

Compounds:

Zidovudine, DDC, and 2',3'-dideoxyinosine (DDI) were purchased from Sigma Chemical Co (St. Louis, MO). All three were reconstituted to 1mM stock solutions in deionized water and stored at -20°C until use. Michael Melnick (Agouron
15 Pharmaceuticals, San Diego) provided Nelfinavir. Manfred Reinecke (Texas Christian University, Fort Fort Worth, TX) provided L-chicoric acid. Both were reconstituted in deionized water and stored at -70°C until use. All stocks were diluted in growth medium and filter-clarified before being tested for cell toxicity and anti-HIV activity.

Anti-HIV Assays:

20 Anti-HIV activity of compounds was determined both alone and in combination using a cytopathicity based assay as described above. This assay utilizes Finter's neutral red dye; protection from HIV-induced cell death is highly correlated with HIV-1 antigen synthesis, RT release, and the formation of infectious progeny virions. All drugs were tested at concentrations well below their toxic doses either
25 alone or in combination. The fifty-percent effective dose (ED_{50}) was calculated for triplicate infections. Mean ED_{50} (shown in Figure 5) were calculated for each drug

against each HIV variant from a minimum of three experiments performed in triplicate.

Mixed Dose Effect Analyses:

Mixed dose effect analyses were performed using the method of Chou and Talalay (*Adv. Enzyme Regul.* 22: 27-55 (1984)) and commercially available software: CalcuSyn for Windows (Biosoft, Ferguson, MO, USA). Experiments were designed at a fixed ratio of drugs; the ratio for each drug combination was determined based on the ED₅₀ of each drug alone against each HIV variant. Combination indices were calculated on representative experiments performed in triplicate according to the following formula of Chou and Talalay:

$$fa/fu = (D/D_m)^m$$

Where fa is the fraction affected by the dose, fu is the unaffected fraction, D is the dose of the drug, D_m is the median-effect dose determined to be the x-intercept of the median-effect plot, and m is the sigmoidicity of the dose-effect curve, determined by the slope of the median-effect plot. The median effect plot is based on the following equation:

$$\log (fa/fu) = m \log (D) - m \log (D_m)$$

20

This equation yields a straight-line $y=mx+b$; therefore, the x intercept is the $\log (D_m)$ value and the slope is m.

The combination index (CI) is based on the multiple drug-effect equation of Chou and Talalay where a CI=1 is additive, greater than 1 is antagonism and less than

1 is synergism. This equation, first defined by Chou and Talalay (*Trends Pharmacol. Sci.* 4: 450-454 (1983)) is:

$$CI = \frac{(D)_1}{(D_x)_1} + \frac{(D)_2}{(D_x)_2}$$

Where D_1 is the dose of drug 1 and D_2 is the dose of drug 2 **in combination** that results in x% inhibition and $(D_x)_1$ and $(D_x)_2$ are the doses of drug 1 and drug 2 **alone** that result in x% inhibition. The results of mixed drug analyses for the pairwise combinations of L-CCA plus DDC, L-CCA plus nelfinavir, and L-CCA plus zidovudine are shown in Tables 4-6 respectively.

Triple Antiviral Agent Measurements:

Anti-HIV Compounds:

ZDV was purchased from Sigma Chemical Company (St. Louis, MO) and was reconstituted with cold deionized water to a final concentration of 1 mM. Protease inhibitor (PI) (AG1350) (Agouron Pharmaceuticals, La Jolla, CA) and reconstituted in 14% ethanol/37.5% DMSO/48.5% H_2O to a final concentration of 7 mM. AG1350 is slightly (less than 10-fold) less active than the recently FDA-approved PI, Viracept®. The L-CCA was dissolved in H_2O to a final concentration of 2.1 mM.

Cells and Virus.

The two clinical isolates were obtained from patients visiting the UCI Medical Center AIDS Clinic under an IRB-approved protocol. HIV_{R19} and HIV_{R45} were obtained approximately three weeks after inoculation with 100 μ l of freshly drawn serum onto MT-2 cells (the time required for the MT-2 cells to become infected).

Previous work has indicated that such isolates of HIV are predominantly syncytium-inducing, rapid-growing, T-cell-tropic isolates of HIV. Cell-free supernatants of HIV_{R19} and HIV_{R45} from MT-2 cells were inoculated onto phytohemagglutinin-stimulated PMBCs, cultured in growth medium supplemented with 11.5% FBS and 20 units of recombinant human IL-2/ml (Boehringer-Mannheim, Indianapolis, IN), and HIV was isolated at peak RT production (7 and 10 days). Both isolates were highly cytopathic and grew to similar titers with similar replication kinetics in tissue culture. The resulting limited passage, cell-free supernatant was directly inoculated onto MT-2 cells for use in antiviral assays.

10 **Cell Toxicity and Anti-HIV Assays:**

Cell toxicity and anti-HIV assays were performed as reported above. Briefly, compounds were diluted 1:1 in growth medium, filter sterilized, and further two-fold serially diluted from 1:8 to 1:1280 in triplicate wells of a microtiter plate. To each 50 µl of diluted drug, 50 µl of growth medium was added followed by 100 µl of MT-2 cell suspension (2×10^5 cells). Cells were incubated with drug for 48 hours at 37°C, then harvested for cell viability in a neutral red dye assay as described. Similar toxicities were also seen if the cells were incubated for 72 hours prior to harvest.

Anti-HIV assays were performed as described above. Based upon cell toxicity data, compounds were diluted in growth medium such that a final 1:4 dilution of the sample would result in a concentration of sample that inhibited MT-2 cell growth by 5% (5% lethal dose, LD₅). The compounds were then two-fold serially diluted in triplicate. To each 50 µl of diluted compound, 50 µl of HIV_{LAI} was added and the virus-drug mixture was incubated for 1 hr at 37°C. Next, 100 µl of MT-2 cell suspension (2×10^5 cells) was added to each well and cells were incubated for 72 hr at 37°C. Final multiplicity of infection (MOI) was 1-5. Cells were harvested to quantitate cytopathic effect using a neutral red dye assay as described. The antiviral concentration reported is the concentration of drug necessary to protect MT-2 cells

from fifty percent viral-induced cell death; this is referred to as the fifty percent effective dose (ED_{50}).

The results reported herein clearly demonstrate that the addition of a first generation IN inhibitor to regimens using either a PI or ZDV improves upon the *in vitro* anti-HIV effect of that regimen. For all of the triple combination studies (Figs. 6-9), all three inhibitors were used at suboptimal concentrations (below the ED_{50}). In addition, if L-CCA is added to ZDV and a PI, one can effectively reduce by at least 33% the amount of ZDV and PI required to provide an equivalent anti-HIV effect. *In vitro* combination analyses may or may not predict how combinations of antiviral agents will behave *in vivo*. For HIV, combinations of protease inhibitors and reverse transcriptase inhibitors demonstrated additive to synergistic effects *in vitro*, which were similar to their *in vivo* effects. With one major limiting factor in anti-HIV combination therapy being the cost of the antiviral agents, especially PIs, such a reduction could substantially increase the number of patients who could be on combination therapy regimens. The results of these *in vitro* studies, if they were to translate into *in vivo* results, could have a substantial impact on both the efficacy and costs of newer anti-HIV therapies.

The addition of L-chicoric acid to either zidovudine or protease inhibitor improved upon the observed anti-HIV activity of either compound alone. When all three drugs were combined, the anti-HIV activity was substantially better than either of the three compounds alone or any combination of two inhibitors. Doses of both zidovudine and protease inhibitor could be reduced by more than 33% for an equivalent anti-HIV effect if L-chicoric acid was added. The improved anti-HIV activity was observed with a tissue culture adapted strain of HIV (HIV_{LA1}) and with limited passage clinical isolates of HIV (HIV_{R19} and HIV_{R45}). These data demonstrate that a first generation HIV integrase inhibitor is at least additive and probably synergistic in combination with existing multi-drug regimens. The modified integrase inhibitors disclosed herein show similar synergistic properties. It is expected that the variations in molecular structure will prove advantageous in actual patient trials. For

example, replacing ester linkages with more stable amide or even aliphatic linkages significantly improves the effectiveness of modified integrase inhibitors. A version of compound 36 in which the amide bonds are replaced with ester bonds is virtually ineffective

5 Many alterations and modifications may be made by those having ordinary skill in the art without departing from the spirit and scope of the invention. Therefore, it must be understood that the illustrated embodiment has been set forth only for the purposes of example and that it should not be taken as limiting the invention which is properly defined by the following claims.

10 The words used in this specification to describe the invention and its various embodiments are to be understood not only in the sense of their commonly defined meanings, but to include by special definition in this specification structure, material or acts beyond the scope of the commonly defined meanings. Thus if an element can be understood in the context of this specification as including more than one meaning,
15 then its use in a claim must be understood as being generic to all possible meanings supported by the specification and by the word itself.

-14-

We claim:

1. A method for treating HIV infections comprising administering a mixture of a reverse transcriptase inhibitor, and/or a protease inhibitor and an integrase inhibitor.
- 5 2. The method of Claim 1 further comprising administering more than one reverse transcriptase inhibitor and/or more than one protease inhibitor.
3. The method of Claim 1 further comprising administering more than one integrase inhibitor.
- 10 4. The method of Claim 2 further comprising administering more than one integrase inhibitor.
5. The method of Claim 1, wherein the integrase inhibitor is selected from a group consisting of chicoric acid 2,3-di(3,4-dihydroxy-dihydroxydihydrocinnamoyl)-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-
15 tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-tartaric acid, 2,3-di-(3,4,5-trihydroxybenzoyl)-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2,-dicaffeoyl-glyceric acid, bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-3,4-dihydroxybenzylidene succinic acid, 2,3-dicaffeoyl-serine, bis-dicaffeoyl-isoserine and 1,4-dicaffeoyl-
20 lysine

AMENDED SHEET

-45-

6. The method of Claim 1, wherein the reverse transcriptase inhibitor is selected from a group consisting of 2',3'-dideoxycytidine, 2',3'-dideoxyinosine and zidovudine.

7. The method of Claim 1, wherein the protease inhibitor is
5 Nelfinavir.

8. A composition for treating HIV infections comprising a mixture of a reverse transcriptase inhibitor, and/or a protease inhibitor and an integrase inhibitor.

9. The composition of Claim 8, wherein the integrase
10 inhibitor is selected from a group consisting of chicoric acid 2,3-di(3,4-dihydroxy-dihydroxydihydrocinnamoyl)-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-tartaric acid, 2,3-di-(3,4,5-trihydroxybenzoyl)-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2-dicaffeoyl-glyceric acid, bis-,3,4-
15 dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-3,4-dihydrodihydroxybenzylidene succinic acid, 2,3-dicaffeoyl-serine, bis-dicaffeoyl-isoserine and 1,4-dicaffeoyl-lysine

10. The composition of Claim 8, wherein the reverse transcriptase inhibitor is selected from a group consisting of 2',3'-
20 dideoxycytidine, 2',3'-dideoxyinosine and zidovudine.

AMENDED SHEET

-46-

11. The composition of Claim 8, wherein the protease inhibitor is Nelfinavir.

12. The composition of Claim 8 further comprising more than one reverse transcriptase inhibitor and/or more than one protease inhibitor.

5 13. The composition of Claim 8 further comprising more than one integrase inhibitor.


14. The composition of Claim 12 further comprising more than one integrase inhibitor.

15. An integrase inhibitor selected from a group consisting of
 10 2,3-di(3,4-dihydroxy-dihydroxydihydrocinnaoyl)-tartaric acid, 2,3-di-(3,4-dihydroxybenzoyl)-tartaric acid, 2,3-di-(3,4-dihydroxyphenylacetyl)-tartaric acid,
 2,3-di-(3,4,5-trihydroxybenzoyl)-tartaric acid, 2,3-dicaffeoyldiamidopropionic acid, 1,2,-dicaffeoyl-glyceric acid, bis,-3,4-dicaffeoyldiamidobenzoic acid, di-3,4-dihydroxybenzylidene succinic acid, di-
 15 3,4-dihydroxybenzylidene succinic acid, 2,3-dicaffeoyl-serine, bis-dicaffeoyl-isoserine and 1,4-dicaffeoyl-lysine

AMENDED SHEET

-47-

16. An integrase inhibitor having the formula:




wherein n is between 0 and 4;

wherein R_2 and R_4 are hydrogen

wherein R_1 and R_3 are selected from the group consisting of
hydrogen, OR_6 , NR_6 and aralkyl groups;

wherein R_6 is



wherein X is a hydrocarbonyl group with from 0 to 10 carbon atoms, Y is selected from $CH=CH$, $N=CH$, $CH=N$, O, S, or NR_7 . m is between 0 and 3, and R_6 is selected from the group consisting of hydrogen, hydroxy, halo, lower alkoxy, alkylcarbonyloxy and alkoxy carbonyloxy or a cyclic carbonate group with hydroxy groups on adjacent carbons; and

wherein R and R_5 are selected from the group consisting of hydrogen, $COOR_7$ and $CONHR_7$;

AMENDED SHEET

-48-

wherein R_7 is selected from the group consisting of hydrogen, alkyl and aralkyl; and

wherein when R and R_5 are COOR_7 and R_7 is hydrogen and R_1 and R_3 are OR_6 , then R_6 and R_8 are hydroxy, m is not 2 and X and Y are not $\text{CH}=\text{CH}$.

5

17. The integrase inhibitor of Claim 16, wherein R_2 and R_4 combine with each other to form a cycloalkyl ring.

18. The integrase inhibitor of Claim 16, wherein R_2 and R_4 are combined with R_1 and R_4 , respectively, to form aromatic rings.

10

19. The integrase inhibitor of Claim 18, wherein the aromatic rings are substituted with from one to three substituents selected from OR_6 and NR_6 groups.

15


20. The integrase inhibitor of Claim 16, wherein when R and R_5 are COOR_7 or CONHR_7 , and R_1 , R_2 and R_3 , R_4 combine to form an arylidene group.

21. The integrase inhibitor of Claim 20, wherein the arylidene group is substituted with from 1 to 3 substituents selected from the group consisting of hydroxy, halo, alkoxy, alkylcarbonyloxy and alkoxycarbonyloxy.

AMENDED SHEET


-49-

22. An integrase inhibitor having the formula:




wherein R is 1,4-dicaffeoyl, n is between 0 and 6 and L comprises
 5 an amino acid linked by an ester or amide bond.

23. An integrase inhibitor having the formula:




wherein R is 1,4-dicaffeoyl, n is between 0 and 6 and L comprises
 10 a chain of between 1 and 6 carbon atoms.

AMENDED SHEET




Compounds 1, 2, 3
L-, D-, m- chicoric Acid

Fig. 1a




Compound 19
1,2-Dicaffeoyl-L-glyceric Acid

Fig. 1b




Compound 22
Bis-(3,4-dihydroxydihydrocinnamoyl)-L-tartaric acid

Fig. 1c




Compound 25
Digalloyl-L-tartaric acid

Fig. 2a




Compound 26
Bis (3,4-dihydroxybenzoyl) L-tartaric acid

Fig. 2b




Compound 28
Bis-(3,4-dihydroxyphenylacetyl)-L-tartaric acid

Fig. 2c




Compound 35
2,3-Dicaffeoyldiamidopropionic acid

Fig. 3a



Compound 36
bis-3,4-dicaffeoyldiamidobenzoic Acid

Fig. 3b



Compound 37
Di-3,4-dihydroxybenzylidene succinic acid

Fig. 3c





**Compound 38****Di-3,4-dihydrodihydroxybenzylidene succinic acid****Fig. 4a****Compound 39****2,3-Dicaffeoyl-L-serine****Fig. 4b****Compound 40****bis-Dicaffeoyl-L-isoserine****Fig. 4c****Compound 41****1,4-Dicaffeoyl-L-Lysine****Fig. 4d**

Fig. 5





Fig. 6






Fig. 8




Fig. 9









Fig. 10




Scheme 1

Fig. 11




Scheme 2

Fig. 12



Scheme 3

Fig. 13



Scheme 4

Fig. 14




Fig. 15




Fig. 16a





Fig. 16b



**DECLARATION
and POWER OF ATTORNEY**

☒ ORIGINAL
☐ CONTINUATION
☐ DIVISIONAL

As a below named inventor, I declare that the information given herein is true, that I believe that I am the original, first and sole inventor (if only one name is listed as 1 below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled.
NOVEL HIV INTEGRASE INHIBITORS AND HIV THERAPY BASED ON DRUG COMBINATIONS INCLUDING INTEGRASE INHIBITORS,
the specification of which is attached hereto unless the following box is checked.

☒ was filed on September 27, 2000 as United States Application Number or PCT International Application Number 09/647,270

My residence, post office address and citizenship are as stated below next to my name.

I acknowledge my duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations § 1.56(a). I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed.

PRIOR FOREIGN APPLICATION(S)

COUNTRY	APPLICATION NUMBER	DATE OF FILING Month Day Year	PRIORITY CLAIMED UNDER 35 U.S.C. 119
PCT	PCT/US99/06700	March 26, 1999	yes
I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application			
60/079,764		March, 27, 1998	(provisional)
60/093,208		July 17, 1998	(provisional)
(Application Serial No.)		(Filing Date)	(Status)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or Agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. ☒ Customer Number

000026021



Send correspondence to:

☒ Customer Number

000026021

Hogan & Hartson L.L.P.
500 South Grand Avenue, Suite 1900
Los Angeles, California 90071

DIRECT TELEPHONE CALLS TO:
KIRCHANSKI, Stefan J.
213-337-6862

(Please Print)

1	Name of Inventor	ROBINSON, W. Edward, Jr.	Residence CITY	Irvine, California 92612	STATE or COUNTRY	United States of America
	Post Office Address	33 Urey Court			CITIZENSHIP	United States of America
2	Name of Inventor	KING, Peter J.	Residence CITY	Atlanta, Georgia 30328	STATE or COUNTRY	United States of America
	Post Office Address	6980 Roswell Road, Apt #F-1			CITIZENSHIP	United States of America
3	Name of Inventor	REINECKE, Manfred G	Residence CITY	Fort Worth, Texas 76109	STATE or COUNTRY	United States of America
	Post Office Address	4105 Hildring Drive East			CITIZENSHIP	United States of America
4	Name of Inventor		Residence CITY		STATE or COUNTRY	
	Post Office Address				CITIZENSHIP	

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 1	SIGNATURE OF INVENTOR 2
DATE 7 December 2000	DATE
SIGNATURE OF INVENTOR 3	SIGNATURE OF INVENTOR 4
DATE	DATE

**DECLARATION
and POWER OF ATTORNEY**

☒ ORIGINAL
☐ CONTINUATION
☐ DIVISIONAL

As a below named inventor, I declare that the information given herein is true, that I believe that I am the original, first and sole inventor (if only one name is listed as 1 below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:
NOVEL HIV INTEGRASE INHIBITORS AND HIV THERAPY BASED ON DRUG COMBINATIONS INCLUDING INTEGRASE INHIBITORS,
the specification of which is attached hereto unless the following box is checked:

☒ was filed on September 27, 2000 as United States Application Number or PCT International Application Number 09/647,270

My residence, post office address and citizenship are as stated below next to my name.

I acknowledge my duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations § 1.56(a). I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above. I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATION(S)

COUNTRY	APPLICATION NUMBER	DATE OF FILING Month Day Year	PRIORITY CLAIMED UNDER 35 U.S.C. 119
PCT	PCT/US99/06700	March 26, 1999	yes
I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application			
66/079,764		March, 27, 1998	(provisional)
60/093,208		July 17, 1998	(provisional)
(Application Serial No.)		(Filing Date)	(Status)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or Agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. ☒ Customer Number 000026021



Send correspondence to:

☒ Customer Number 000026021

Hogan & Hartson LLP
500 South Grand Avenue, Suite 1900
Los Angeles, California 90071
PATENT & TRADEMARK OFFICE

DIRECT TELEPHONE CALLS TO:
KIRCHANSKI, Stefan J.
213-337-6862

(Please Print)

1	Name of Inventor	ROBINSON, W. Edward, Jr.	Residence CITY	Irvine, California 92612	STATE or COUNTRY	United States of America
	Post Office Address	33 Urey Court			CITIZENSHIP	United States of America
2	Name of Inventor	KING, Peter J.	Residence: CITY	Atlanta, Georgia 30328	STATE or COUNTRY	United States of America
	Post Office Address	6980 Roswell Road, Apt. #F-1			CITIZENSHIP	United States of America
3	Name of Inventor	REINECKE, Manfred G.	Residence: CITY	Fort Worth, Texas 76109	STATE or COUNTRY	United States of America
	Post Office Address	4105 Hildring Drive East			CITIZENSHIP	United States of America
4	Name of Inventor		Residence: CITY		STATE or COUNTRY	
	Post Office Address				CITIZENSHIP	

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

SIGNATURE OF INVENTOR 1	SIGNATURE OF INVENTOR 2
DATE	DATE 12/12/00
SIGNATURE OF INVENTOR 3	SIGNATURE OF INVENTOR 4
DATE	DATE

DECLARATION and POWER OF ATTORNEY

☒ ORIGINAL
☐ CONTINUATION
☐ DIVISIONAL

As a below named inventor, I declare that the information given herein is true, that I believe that I am the original, first and sole inventor (if only one name is listed as 1 below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:
NOVEL HIV INTEGRASE INHIBITORS AND HIV THERAPY BASED ON DRUG COMBINATIONS INCLUDING INTEGRASE INHIBITORS,
the specification of which is attached hereto unless the following box is checked:
☒ was filed on September 27, 2000 as United States Application Number or PCT International Application Number 09/647,270

My residence, post office address and citizenship are as stated below next to my name.
I acknowledge my duty to disclose information which is material to the patentability of this application in accordance with Title 37, Code of Federal Regulations § 1.56(a)
I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.
I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN APPLICATION(S)

COUNTRY	APPLICATION NUMBER	DATE OF FILING Month Day Year	PRIORITY CLAIMED UNDER 35 U.S.C. 119
PCT	PCT/US99/06700 ✓	March 26, 1999	yes
I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application			
	06/079,764	March, 27, 1998	(provisional)
	60/093,208	July 17, 1998	(provisional)
(Application Serial No.)		(Filing Date)	(Status)

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or Agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith. ☒ Customer Number **000026021**



Send correspondence to:

☒ Customer Number **000026021**

Hogan & Hartson L.L.P.
500 South Grand Avenue, Suite 1900
Los Angeles, California 90071
PATENT & TRADEMARK OFFICE

DIRECT TELEPHONE CALLS TO:
KIRCHANSKI, Stefan J.
213-337-6862

(Please Print)

1	Name of Inventor	Residence: CITY	STATE or COUNTRY
	ROBINSON, W. Edward, Jr.	Irvine, California 92612	United States of America
2	Post Office Address	CITIZENSHIP	
	33 Urey Court	United States of America	
2	Name of Inventor	Residence: CITY	STATE or COUNTRY
	KING, Peter J	Atlanta, Georgia 30328	United States of America
3-003	Post Office Address	CITIZENSHIP	
	6980 Roswell Road, Apt #F-1	United States of America	
4	Name of Inventor	Residence: CITY	STATE or COUNTRY
	REINECKE, Manfred G.	Fort Worth, Texas 76109	United States of America
4	Post Office Address	CITIZENSHIP	
	4105 Hildring Drive East	United States of America	
4	Name of Inventor	Residence: CITY	STATE or COUNTRY
4	Post Office Address	CITIZENSHIP	

I further declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon

SIGNATURE OF INVENTOR 1	SIGNATURE OF INVENTOR 2
DATE	DATE
SIGNATURE OF INVENTOR 3 X <u>Manfred G. Reinecke</u>	SIGNATURE OF INVENTOR 4
DATE X <u>12/7/00</u>	DATE